https://www.stadtwiki-strausberg.de/index.php?action=history&feed=atom&title=5F-ADB_Wikipedia 2026-06-24T09:07:01Z Versionsgeschichte dieser Seite in Stadtwiki Strausberg MediaWiki 1.33.1 https://www.stadtwiki-strausberg.de/index.php?title=5F-ADB_Wikipedia&diff=34939&oldid=prev 2026-06-21T18:45:19Z

<p></p> <table class="diff diff-contentalign-left" data-mw="interface"> <col class="diff-marker" /> <col class="diff-content" /> <col class="diff-marker" /> <col class="diff-content" /> <tr class="diff-title" lang="de"> <td colspan="2" style="background-color: #fff; color: #222; text-align: center;">← Nächstältere Version</td> <td colspan="2" style="background-color: #fff; color: #222; text-align: center;">Version vom 21. Juni 2026, 18:45 Uhr</td> </tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l1" >Zeile 1:</td> <td colspan="2" class="diff-lineno">Zeile 1:</td></tr> <tr><td class='diff-marker'>−</td><td style="color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del class="diffchange diffchange-inline">Tremors were observed </del>in <del class="diffchange diffchange-inline">mice 30 minutes following 1 mg/kg AMB</del>-<del class="diffchange diffchange-inline">FUBINACA in the present study</del>. <del class="diffchange diffchange-inline">Pretreatment times and dose ranges for the drug discrimination assay were selected based on the time </del>of <del class="diffchange diffchange-inline">peak depression </del>in the <del class="diffchange diffchange-inline">locomotor activity assay in mice. Average potency of the discriminative stimulus effects of early compounds was 0.81±0.17 </del>mg/kg <del class="diffchange diffchange-inline">(Gatch et al</del>.<del class="diffchange diffchange-inline">, 2014</del>)<del class="diffchange diffchange-inline">, whereas </del>the <del class="diffchange diffchange-inline">potency of a recent set was 0</del>.<del class="diffchange diffchange-inline">09±0.03 </del>mg/kg <del class="diffchange diffchange-inline">(Gatch et al</del>.<del class="diffchange diffchange-inline">, 2018</del>), and the <del class="diffchange diffchange-inline">potency of the current set is 0</del>.<del class="diffchange diffchange-inline">05±0.01 mg/kg. Short</del>-<del class="diffchange diffchange-inline">onset, short</del>-<del class="diffchange diffchange-inline">acting compounds have </del>a <del class="diffchange diffchange-inline">greater abuse liability</del>, and <del class="diffchange diffchange-inline">long</del>-<del class="diffchange diffchange-inline">acting compounds pose problems </del>of <del class="diffchange diffchange-inline">long</del>-<del class="diffchange diffchange-inline">acting adverse effects and interactions with other </del>drugs<del class="diffchange diffchange-inline">. The duration </del>of <del class="diffchange diffchange-inline">action </del>of the <del class="diffchange diffchange-inline">synthetic cannabinoids tested using the 8</del>-<del class="diffchange diffchange-inline">h protocol have varied widely</del>, <del class="diffchange diffchange-inline">with some producing </del>a <del class="diffchange diffchange-inline">duration </del>of <del class="diffchange diffchange-inline">action no longer than 1 h</del>, <del class="diffchange diffchange-inline">others producing a duration of action between 1–2 h</del>, and <del class="diffchange diffchange-inline">others lasting more than 2 h</del>. <del class="diffchange diffchange-inline">There seems to be a trend of newer synthetic </del>cannabinoids <del class="diffchange diffchange-inline">being more potent than earlier compound</del>&lt;br&gt;&lt;br&gt;&lt;br&gt;<del class="diffchange diffchange-inline">Although there were reports on the metabolism </del>of <del class="diffchange diffchange-inline">4F</del>-MDMB-<del class="diffchange diffchange-inline">BINACA using in</del>-<del class="diffchange diffchange-inline">vivo and various in-vitro models</del>, <del class="diffchange diffchange-inline">studies were either conducted using small in-vivo sample size such as 1 to 4 samples [5, 29] or in closed environments such as forensic psychiatric wards and prisons </del>. The <del class="diffchange diffchange-inline">hepatic cell line HepG2 is often used as an initial screen as it is known to produce high reproducibility results with relatively stable enzyme concentration</del>, <del class="diffchange diffchange-inline">although they </del>are <del class="diffchange diffchange-inline">limited by </del>the <del class="diffchange diffchange-inline">low-level expression </del>of <del class="diffchange diffchange-inline">several metabolizing enzymes, including the cytochrome P450 </del>(<del class="diffchange diffchange-inline">CYP</del>) <del class="diffchange diffchange-inline">class </del>of <del class="diffchange diffchange-inline">proteins [17, 18]. In</del>-<del class="diffchange diffchange-inline">vitro metabolism studies are generally used to complement these data using perfused organs</del>, <del class="diffchange diffchange-inline">tissue or cell cultures and microsomal preparations amongst </del>which <del class="diffchange diffchange-inline">pooled human liver microsomes (HLM) </del>have <del class="diffchange diffchange-inline">been frequently used </del>to <del class="diffchange diffchange-inline">elucidate metabolism </del>of <del class="diffchange diffchange-inline">SCBs [12,13,14,15,16]</del>. <del class="diffchange diffchange-inline">Since most SCBs are found extensively </del>in <del class="diffchange diffchange-inline">metabolized forms </del>in <del class="diffchange diffchange-inline">urine, the identification of metabolites is of vital importance for forensic </del>and <del class="diffchange diffchange-inline">clinical toxicologists</del>. <del class="diffchange diffchange-inline">Identifying SCB intake </del>and <del class="diffchange diffchange-inline">its correlating specific adverse effects require rapid elucidation </del>of <del class="diffchange diffchange-inline">these SCBs</del>. <del class="diffchange diffchange-inline">The proliferation of SCBs has become a global challenge as new compounds are rapidly introduced into the illegal drug market to evade existing drug law</del>&lt;br&gt;&lt;br&gt;<del class="diffchange diffchange-inline">&lt;br&gt;Test </del>2 <del class="diffchange diffchange-inline">was performed everyday for </del>5 <del class="diffchange diffchange-inline">days after consecutive administration of </del>the <del class="diffchange diffchange-inline">substances</del>, <del class="diffchange diffchange-inline">including negative (vehicle) </del>and <del class="diffchange diffchange-inline">positive </del>(<del class="diffchange diffchange-inline">methamphetamine</del>) <del class="diffchange diffchange-inline">controls</del>. <del class="diffchange diffchange-inline">After </del>the <del class="diffchange diffchange-inline">last administration</del>, <del class="diffchange diffchange-inline">the first trial </del>was <del class="diffchange diffchange-inline">performed</del>. <del class="diffchange diffchange-inline">Morris water maze test was performed </del>to <del class="diffchange diffchange-inline">evaluate </del>the <del class="diffchange diffchange-inline">changes </del>of <del class="diffchange diffchange-inline">learning </del>and <del class="diffchange diffchange-inline">memory function through administration </del>of the <del class="diffchange diffchange-inline">test substances</del>. <del class="diffchange diffchange-inline">Generally</del>, <del class="diffchange diffchange-inline">neurotoxicity </del>of <del class="diffchange diffchange-inline">a substance is evaluated by animal behavioral aspects</del>, <del class="diffchange diffchange-inline">i.e. functional observation battery </del>(<del class="diffchange diffchange-inline">FOB</del>) <del class="diffchange diffchange-inline">tests </del>(<del class="diffchange diffchange-inline">O’Callaghan et al</del>.<del class="diffchange diffchange-inline">, 2014)</del>. <del class="diffchange diffchange-inline">Our results suggest </del>that <del class="diffchange diffchange-inline">JWH</del>-<del class="diffchange diffchange-inline">081 and JWH</del>-<del class="diffchange diffchange-inline">210 may 4F ADB be neurotoxic substances through changing neuronal cell damages</del>, <del class="diffchange diffchange-inline">especially </del>in the <del class="diffchange diffchange-inline">core shell part </del>of <del class="diffchange diffchange-inline">nucleus accumbens.&lt;br&gt;About Powder JWH-2</del>&lt;br&gt;&lt;br&gt;&lt;br&gt;Locomotor activity in mice was tested to screen for locomotor depressant effects and to identify behaviorally-active dose ranges and times of peak effect. Previous studies have demonstrated that these compounds have chemical structures similar to synthetic cannabinoids known to have substantial abuse liability and act at the CB1 receptor. Tremors were <del class="diffchange diffchange-inline">not </del>observed following AMB-FUBINACA <del class="diffchange diffchange-inline">during </del>the <del class="diffchange diffchange-inline">drug discrimination study</del>, <del class="diffchange diffchange-inline">but </del>the <del class="diffchange diffchange-inline">maximum </del>dose tested <del class="diffchange diffchange-inline">was only </del>0.<del class="diffchange diffchange-inline">1 </del>mg/kg<del class="diffchange diffchange-inline">, which </del>is <del class="diffchange diffchange-inline">10-fold lower than the dose </del>that <del class="diffchange diffchange-inline">produced tremors in </del>the <del class="diffchange diffchange-inline">mice. AMB</del>-<del class="diffchange diffchange-inline">FUBINACA has been implicated in severe adverse effects in recreational users </del>(<del class="diffchange diffchange-inline">Adams </del>et al., <del class="diffchange diffchange-inline">2017; Hamilton et al., 2017</del>), <del class="diffchange diffchange-inline">which suggests that </del>the <del class="diffchange diffchange-inline">range between behaviorally active and toxic doses of AMB-FUBINACA is narrow. Following that line of reasoning</del>, <del class="diffchange diffchange-inline">it should also be noted that some of the more recent compounds produced non</del>-<del class="diffchange diffchange-inline">linear dose-effect curves and one compound produced an inverted U-shaped dose</del>-<del class="diffchange diffchange-inline">effect</del>, <del class="diffchange diffchange-inline">such that intermediate dose fully substituted</del>, but <del class="diffchange diffchange-inline">higher doses did </del>not (<del class="diffchange diffchange-inline">Gatch and Forster</del>, <del class="diffchange diffchange-inline">2018</del>). <del class="diffchange diffchange-inline">All </del>of the compounds <del class="diffchange diffchange-inline">identified as available on </del>the <del class="diffchange diffchange-inline">recreational market </del>and <del class="diffchange diffchange-inline">submitted to our laboratory by the US Drug Enforcement Agency for testing have fully substituted </del>at <del class="diffchange diffchange-inline">some dose </del>(<del class="diffchange diffchange-inline">Gatch and Forster 2014</del>, 2015, 2016<del class="diffchange diffchange-inline">, 2018)</del>; <del class="diffchange diffchange-inline">however; it is important to note that not all structural congeners are active (Wiley </del>et al., <del class="diffchange diffchange-inline">2012&lt;br&gt;&lt;br&gt;&lt;br&gt;LC</del>-<del class="diffchange diffchange-inline">QTOF</del>-<del class="diffchange diffchange-inline">MS represents a significant advancement in the field of drug detection</del>, <del class="diffchange diffchange-inline">offering higher sensitivity, specificity, and a broader spectrum of detectable substances</del>. <del class="diffchange diffchange-inline">Despite all negative results in </del>the <del class="diffchange diffchange-inline">point-of-care test for recreational drugs</del>, the <del class="diffchange diffchange-inline">liquid chromatography-quadrupole time-of-flight mass spectrometry (LC-QTOF-MS) analysis showed that the liquid of the e-cigarette contained ADB-BUTINACA, a synthetic cannabinoid. We report a 27-year-old man who </del>was <del class="diffchange diffchange-inline">admitted to the emergency room because of sudden [https://cannabinoidsrc4f-adb</del>.<del class="diffchange diffchange-inline">com</del>/ <del class="diffchange diffchange-inline">4F ADB] headache</del>, <del class="diffchange diffchange-inline">nausea, vertigo, red eyes and palpitations. Synthetic cannabinoids are gaining popularity globally and detection </del>is <del class="diffchange diffchange-inline">not commonly available</del>.&lt;br&gt;<del class="diffchange diffchange-inline">Data availability &lt;br&gt;When clinical presentation and/or initial DOA testing results are inconclusive, additional testing with LC-QTOF-MS can be valuable and is recommended. SCRAs and other NPS may not be detected by point-of-care DOA tests. In this case, the point-of-care DOA urine screening was not able to detect the synthetic cannabinoid ADB-BUTINAC</del></div></td><td class='diff-marker'>+</td><td style="color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins class="diffchange diffchange-inline">Observation item 1st injection 2nd injection 3rd injection 4th injection 5th injection Con. All groups treated with tested synthetic cannabinoids showed decreased weight gain rate </ins>in <ins class="diffchange diffchange-inline">a dose</ins>-<ins class="diffchange diffchange-inline">dependent manner</ins>. <ins class="diffchange diffchange-inline">A total </ins>of <ins class="diffchange diffchange-inline">5 mice </ins>in the <ins class="diffchange diffchange-inline">JWH-081 (5 </ins>mg/kg<ins class="diffchange diffchange-inline">, i.p</ins>.) <ins class="diffchange diffchange-inline">treated group and 6 mice in </ins>the <ins class="diffchange diffchange-inline">[https://cannabinoidsrc4f-adb</ins>.<ins class="diffchange diffchange-inline">com/ Read Much more] JWH-210 (5 </ins>mg/kg<ins class="diffchange diffchange-inline">, i.p</ins>.) <ins class="diffchange diffchange-inline">treated group showed loss of traction</ins>, <ins class="diffchange diffchange-inline">of which 4 </ins>and <ins class="diffchange diffchange-inline">5 showed tremor, respectively. Memory retention was measured after </ins>the <ins class="diffchange diffchange-inline">memory acquisition was tested as a probe trial</ins>.<ins class="diffchange diffchange-inline">&lt;br&gt;About Powder JWH-2&lt;br&gt;&lt;br&gt;&lt;br&gt;LC</ins>-<ins class="diffchange diffchange-inline">QTOF</ins>-<ins class="diffchange diffchange-inline">MS represents </ins>a <ins class="diffchange diffchange-inline">significant advancement in the field of drug detection, offering higher sensitivity, specificity</ins>, and <ins class="diffchange diffchange-inline">a broader spectrum of detectable substances. Despite all negative results in the point</ins>-of-<ins class="diffchange diffchange-inline">care test for recreational </ins>drugs<ins class="diffchange diffchange-inline">, the liquid chromatography-quadrupole time-</ins>of<ins class="diffchange diffchange-inline">-flight mass spectrometry (LC-QTOF-MS) analysis showed that the liquid </ins>of the <ins class="diffchange diffchange-inline">e-cigarette contained ADB</ins>-<ins class="diffchange diffchange-inline">BUTINACA</ins>, a <ins class="diffchange diffchange-inline">synthetic cannabinoid. We report a 27-year-old man who was admitted to the emergency room because </ins>of <ins class="diffchange diffchange-inline">sudden Read Much more headache, nausea</ins>, <ins class="diffchange diffchange-inline">vertigo</ins>, <ins class="diffchange diffchange-inline">red eyes </ins>and <ins class="diffchange diffchange-inline">palpitations</ins>. <ins class="diffchange diffchange-inline">Synthetic </ins>cannabinoids <ins class="diffchange diffchange-inline">are gaining popularity globally and detection is not commonly availabl</ins>&lt;br&gt;&lt;br&gt;&lt;br&gt;<ins class="diffchange diffchange-inline">Synthetic cannabinoids have consistently been shown to produce discriminative stimulus effects similar to those Read Much more </ins>of <ins class="diffchange diffchange-inline">Δ9</ins>-<ins class="diffchange diffchange-inline">THC (Bannister and Connor, 2018), and </ins>MDMB-<ins class="diffchange diffchange-inline">FUBINACA fully substituted for Δ9</ins>-<ins class="diffchange diffchange-inline">THC (Gamage et al.</ins>, <ins class="diffchange diffchange-inline">2018)</ins>. The <ins class="diffchange diffchange-inline">chemical structures of the recent synthetic cannabinoids are unlike that of Δ9-THC</ins>, <ins class="diffchange diffchange-inline">but </ins>are <ins class="diffchange diffchange-inline">largely based on </ins>the <ins class="diffchange diffchange-inline">structure </ins>of <ins class="diffchange diffchange-inline">older synthetic cannabinoids that are known to have substantial abuse liability </ins>(<ins class="diffchange diffchange-inline">Fig. 1</ins>)<ins class="diffchange diffchange-inline">. All 5 compounds decreased locomotor activity and produced discriminative stimulus effects similar to those </ins>of <ins class="diffchange diffchange-inline">Δ9</ins>-<ins class="diffchange diffchange-inline">THC</ins>, which <ins class="diffchange diffchange-inline">suggests they may </ins>have <ins class="diffchange diffchange-inline">abuse liability similar </ins>to <ins class="diffchange diffchange-inline">that </ins>of <ins class="diffchange diffchange-inline">Δ9-THC</ins>. <ins class="diffchange diffchange-inline">Subsequent testing identified 5F-ADB to have been present </ins>in <ins class="diffchange diffchange-inline">a total of ten people who had died from unexplained drug overdoses </ins>in <ins class="diffchange diffchange-inline">Japan between September 2014 </ins>and <ins class="diffchange diffchange-inline">December 2014</ins>. <ins class="diffchange diffchange-inline">AMB-FUBINACA produced tremors </ins>and <ins class="diffchange diffchange-inline">may be </ins>of <ins class="diffchange diffchange-inline">increased risk in human recreational users</ins>.&lt;br&gt;<ins class="diffchange diffchange-inline">Michael B Gatch </ins>&lt;br&gt;<ins class="diffchange diffchange-inline">Duration of the locomotor depression increased over dose from 30 min following 0.1 mg/kg to </ins>2<ins class="diffchange diffchange-inline">.</ins>5 <ins class="diffchange diffchange-inline">h following 1 mg/kg. Substantial depressant effects were observed within </ins>the <ins class="diffchange diffchange-inline">first 10 min</ins>, and <ins class="diffchange diffchange-inline">maximal depression was observed between 0–30 min following administration. Tremors were observed 30 minutes following 1 mg/kg AMB-FUBINACA in 3 of 8 mice </ins>(<ins class="diffchange diffchange-inline">data not shown</ins>). <ins class="diffchange diffchange-inline">Substantial depressant effects were observed within </ins>the <ins class="diffchange diffchange-inline">first 10 min</ins>, <ins class="diffchange diffchange-inline">and maximal depression </ins>was <ins class="diffchange diffchange-inline">observed between 10–40 min and lasted up to 2</ins>.<ins class="diffchange diffchange-inline">5 </ins>to <ins class="diffchange diffchange-inline">3 h at </ins>the <ins class="diffchange diffchange-inline">highest dose tested (0.5 mg/kg). Figure 1 shows average horizontal activity counts/10 min as a function </ins>of <ins class="diffchange diffchange-inline">time (0–4 h) </ins>and <ins class="diffchange diffchange-inline">dose of Δ9-TH&lt;br&gt;&lt;br&gt;Figure 1. &lt;br&gt;Each training session lasted a maximum </ins>of <ins class="diffchange diffchange-inline">10 min, and </ins>the <ins class="diffchange diffchange-inline">rats could earn up to 20 food pellets</ins>. <ins class="diffchange diffchange-inline">Thirty minutes prior to the training sessions</ins>, <ins class="diffchange diffchange-inline">rats received an injection </ins>of <ins class="diffchange diffchange-inline">either vehicle or Δ9-THC and were subsequently placed in the behavior-testing chambers</ins>, <ins class="diffchange diffchange-inline">where food </ins>(<ins class="diffchange diffchange-inline">45-mg food pellets; Bio-Serve, Frenchtown, NJ</ins>) <ins class="diffchange diffchange-inline">was available as a reinforcer for every ten responses </ins>(<ins class="diffchange diffchange-inline">FR10) on a designated injection appropriate lever</ins>. <ins class="diffchange diffchange-inline">A houselight was centered over the hopper close to the ceiling and was illuminated only when the levers were active</ins>. <ins class="diffchange diffchange-inline">Each dose range included doses </ins>that <ins class="diffchange diffchange-inline">were without effect to those producing at least 50% depression compared to vehicle control. Twenty</ins>-<ins class="diffchange diffchange-inline">four male Sprague</ins>-<ins class="diffchange diffchange-inline">Dawley rats were obtained from Envigo (Houston, TX). Male ND4 Swiss–Webster mice were obtained from Envigo (Houston</ins>, <ins class="diffchange diffchange-inline">TX) at approximately 8 weeks of age and maintained </ins>in the <ins class="diffchange diffchange-inline">University </ins>of <ins class="diffchange diffchange-inline">North Texas Health Science Center (UNTHSC) animal facility for two weeks prior to testin</ins>&lt;br&gt;&lt;br&gt;<ins class="diffchange diffchange-inline">4. Drugs </ins>&lt;br&gt;<ins class="diffchange diffchange-inline">In general, the locomotor depressant and discriminative stimulus effects have been observed at doses that do not produce adverse effects, although tremors were observed upon handling in mice that received JWH-210 (Gatch et al., 2016), and 5F-AMB produced sustained vocalization and convulsions in rats (Gatch et al., 2018). All of the synthetic cannabinoids tested in the present study fully substituted for the discriminative stimulus effects of Δ9-THC. Subsequently, a one-way analysis of variance was conducted on horizontal activity counts for the 30-min period of maximal effect, and planned comparisons were conducted for each dose against the vehicle control using single degree-of-freedom F tests. A two-way analysis of variance, with dose as a between groups factor and time as a within subject factor, was conducted on horizontal activity counts/10 min interval. </ins>Locomotor activity in mice was tested to screen for locomotor depressant effects and to identify behaviorally-active dose ranges and times of peak effect. Previous studies have demonstrated that these compounds have chemical structures similar to synthetic cannabinoids known to have substantial abuse liability and act at the CB1 receptor<ins class="diffchange diffchange-inline">.&lt;br&gt;Michael B Gatch &lt;br&gt;Substantial depressant effects were observed within the first 10 min, and maximal depression was observed between 0–30 min following administration</ins>. Tremors were observed <ins class="diffchange diffchange-inline">30 minutes </ins>following <ins class="diffchange diffchange-inline">1 mg/kg </ins>AMB-FUBINACA <ins class="diffchange diffchange-inline">in 3 of 8 mice (data not shown). Substantial depressant effects were observed within </ins>the <ins class="diffchange diffchange-inline">first 10 min</ins>, <ins class="diffchange diffchange-inline">and maximal depression was observed between 10–40 min and lasted up to 2.5 to 3 h at </ins>the <ins class="diffchange diffchange-inline">Read Much more highest </ins>dose tested <ins class="diffchange diffchange-inline">(</ins>0.<ins class="diffchange diffchange-inline">5 </ins>mg/kg<ins class="diffchange diffchange-inline">).&lt;br&gt;Figure 1. &lt;br&gt;There </ins>is <ins class="diffchange diffchange-inline">indication </ins>that <ins class="diffchange diffchange-inline">at least some of </ins>the <ins class="diffchange diffchange-inline">first</ins>-<ins class="diffchange diffchange-inline">generation synthetic cannabinoids act at receptors other than cannabinoid CB1 and CB2 </ins>(<ins class="diffchange diffchange-inline">Wiley </ins>et al., <ins class="diffchange diffchange-inline">2016</ins>), <ins class="diffchange diffchange-inline">and a compound from </ins>the <ins class="diffchange diffchange-inline">present study</ins>, <ins class="diffchange diffchange-inline">5F</ins>-<ins class="diffchange diffchange-inline">MDMB</ins>-<ins class="diffchange diffchange-inline">PINACA</ins>, <ins class="diffchange diffchange-inline">was found to activate midbrain dopamine neurons</ins>, but not <ins class="diffchange diffchange-inline">serotonin neurons </ins>(<ins class="diffchange diffchange-inline">Asaoka et al.</ins>, <ins class="diffchange diffchange-inline">2016</ins>). <ins class="diffchange diffchange-inline">As previously mentioned, all </ins>of the compounds <ins class="diffchange diffchange-inline">tested in </ins>the <ins class="diffchange diffchange-inline">present study (MDMB-PINACA, MDMB-CHMICA, MDMB-FUBINACA, ADB-FUBINACA, </ins>and <ins class="diffchange diffchange-inline">AMB-FUBINACA) act as agonists </ins>at <ins class="diffchange diffchange-inline">CB1 receptors </ins>(<ins class="diffchange diffchange-inline">Banister et al.</ins>, 2015, 2016; <ins class="diffchange diffchange-inline">Gamage </ins>et al., <ins class="diffchange diffchange-inline">2018), which suggests these compounds will produce Δ9</ins>-<ins class="diffchange diffchange-inline">THC</ins>-<ins class="diffchange diffchange-inline">like effects</ins>, <ins class="diffchange diffchange-inline">including abuse liability</ins>. <ins class="diffchange diffchange-inline">Tremors were not observed following AMB-FUBINACA during </ins>the <ins class="diffchange diffchange-inline">drug discrimination study</ins>, <ins class="diffchange diffchange-inline">but </ins>the <ins class="diffchange diffchange-inline">maximum dose tested </ins>was <ins class="diffchange diffchange-inline">only 0</ins>.<ins class="diffchange diffchange-inline">1 mg</ins>/<ins class="diffchange diffchange-inline">kg</ins>, <ins class="diffchange diffchange-inline">which </ins>is <ins class="diffchange diffchange-inline">10-fold lower than the dose that produced tremors in the mice</ins>.&lt;br&gt;<ins class="diffchange diffchange-inline">Michael B Gat</ins></div></td></tr> <!-- diff cache key stadtwiki:diff::1.12:old-34935:rev-34939 --> </table>

ScarlettCagle66 https://www.stadtwiki-strausberg.de/index.php?title=5F-ADB_Wikipedia&diff=34935&oldid=prev 2026-06-21T18:42:20Z

<p></p> <table class="diff diff-contentalign-left" data-mw="interface"> <col class="diff-marker" /> <col class="diff-content" /> <col class="diff-marker" /> <col class="diff-content" /> <tr class="diff-title" lang="de"> <td colspan="2" style="background-color: #fff; color: #222; text-align: center;">← Nächstältere Version</td> <td colspan="2" style="background-color: #fff; color: #222; text-align: center;">Version vom 21. Juni 2026, 18:42 Uhr</td> </tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l1" >Zeile 1:</td> <td colspan="2" class="diff-lineno">Zeile 1:</td></tr> <tr><td class='diff-marker'>−</td><td style="color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>Locomotor activity in mice was tested to screen for locomotor depressant effects and to identify behaviorally-active dose ranges and times of peak effect. Previous studies have demonstrated that these compounds have chemical structures similar to synthetic cannabinoids known to have substantial abuse liability and act at the CB1 receptor. Tremors were not observed following AMB-FUBINACA during the drug discrimination study, but the maximum dose tested was only 0.1 mg/kg, which is 10-fold lower than the dose that produced tremors in the mice. AMB-FUBINACA has been implicated in severe adverse effects in recreational users (Adams et al., 2017; Hamilton et al., 2017), which suggests that the range between behaviorally active and toxic doses of AMB-FUBINACA is narrow. Following that line of reasoning, it should also be noted that some of the more recent compounds produced non-linear dose-effect curves and one compound produced an inverted U-shaped dose-effect, such that intermediate dose fully substituted, but higher doses did not (Gatch and Forster, 2018). All of the compounds identified as available on the recreational market and submitted to our laboratory by the US Drug Enforcement Agency for testing have fully substituted at some dose (Gatch and Forster 2014, 2015, 2016, 2018); however; it is important to note that not all structural congeners are active (Wiley et al., 2012&lt;br&gt;&lt;br&gt;&lt;br&gt;<del class="diffchange diffchange-inline">Taken together these data further confirmed </del>the <del class="diffchange diffchange-inline">structure elucidation </del>of <del class="diffchange diffchange-inline">B16</del>. <del class="diffchange diffchange-inline">The precursor ion m/z 276 (B1) detected, which was 74 Da lower than that for </del>the <del class="diffchange diffchange-inline">4F</del>-<del class="diffchange diffchange-inline">MDMB</del>-<del class="diffchange diffchange-inline">BINACA ester hydrolysis metabolite (B22)</del>, <del class="diffchange diffchange-inline">indicated N</del>-<del class="diffchange diffchange-inline">dealkylation </del>of <del class="diffchange diffchange-inline">B22. The precursor ion m/z 348 and product ion detected at m/z 217 </del>(<del class="diffchange diffchange-inline">B2</del>) <del class="diffchange diffchange-inline">identified was 2 Da less than </del>the <del class="diffchange diffchange-inline">4F</del>-<del class="diffchange diffchange-inline">MDMB</del>-<del class="diffchange diffchange-inline">BINACA ester hydrolysis metabolite (B22)</del>, <del class="diffchange diffchange-inline">indicating oxidative defluorination (loss </del>of <del class="diffchange diffchange-inline">fluorine with addition of hydroxy </del>[https://cannabinoidsrc4f-adb.com/ <del class="diffchange diffchange-inline">5CL ADBA powder</del>] <del class="diffchange diffchange-inline">group&lt;br&gt;&lt;br&gt;&lt;br&gt;In summary</del>, <del class="diffchange diffchange-inline">JWH-210 Chemical Powder stands out as a high-quality research compound designed for professionals who demand accuracy</del>, <del class="diffchange diffchange-inline">consistency</del>, and <del class="diffchange diffchange-inline">reliability</del>. <del class="diffchange diffchange-inline">This commitment to 5CL ADBA powder quality makes it a trusted option for professionals who require dependable compounds for their work. From sourcing raw materials to final packaging, every stage of the process is monitored to ensure compliance with laboratory-grade expectations. This makes it an ideal choice for laboratories that prioritize both efficiency </del>and <del class="diffchange diffchange-inline">compliance with research standards.&lt;br&gt;Key Features and Specifications to Evaluate &lt;br&gt;Higher prices often reflect rigorous quality control rather than markup alone. This compound </del>is <del class="diffchange diffchange-inline">appropriate only for authorized professionals conducting lawful research or analysis. For legitimate applications, only fully characterized, independently tested JWH-210 5CL ADBA powder should be considered</del>.&lt;br&gt;<del class="diffchange diffchange-inline">How to Choose Powder JWH-210 </del>&lt;br&gt;<del class="diffchange diffchange-inline">This dual-use nature underscores the importance of responsible sourcing </del>and <del class="diffchange diffchange-inline">strict adherence to legal frameworks. Forensic labs</del>, <del class="diffchange diffchange-inline">public health researchers, and customs officials use authentic samples like JWH</del>-<del class="diffchange diffchange-inline">210 to distinguish between legal and illegal compounds in seized materials. For those seeking a dependable compound for analytical purposes, JWH</del>-<del class="diffchange diffchange-inline">210 Chemical Powder provides a trusted </del>and <del class="diffchange diffchange-inline">effective solution</del>. <del class="diffchange diffchange-inline">With its carefully controlled production process, stable composition, </del>and <del class="diffchange diffchange-inline">secure packaging, it remains a valuable resource for laboratory</del>-<del class="diffchange diffchange-inline">based research.&lt;br&gt;Is JWH</del>-<del class="diffchange diffchange-inline">210 Legal? &lt;br&gt;A total of 2 and 3 methamphetamine treated mice fell from the spinning rod 30 min and 2 hr after the administration, respectively</del>. <del class="diffchange diffchange-inline">After the first injection</del>, <del class="diffchange diffchange-inline">6 mice of </del>the <del class="diffchange diffchange-inline">positive control group (methamphetamine, 5 mg/kg, i.p.) showed loss of traction, of which 4 showed tremor. Most of the abnormalities were normalized in synthetic cannabinoid treated mice although those abnormal behaviors remained in methamphetamine treated animals after 2 hr of administration. Brain samples were prepared from the mice after the last administration of test substance&lt;br&gt;&lt;br&gt;The test apparatus for the locomotor activity test was designed to measure locomotor activity automatically using UV system (AM 1051, Benwick Electronics, Benwick, UK) when experimental animals moved in the chambe&lt;br&gt;&lt;br&gt;Figure 1. &lt;br&gt;Each training session lasted a maximum of 10 min, and the rats could earn up to 20 food pellets. Thirty minutes prior to the training sessions, rats received an injection </del>of <del class="diffchange diffchange-inline">either vehicle or Δ9</del>-<del class="diffchange diffchange-inline">THC and were subsequently placed in the behavior-testing chambers, where food (45-mg food pellets; Bio-Serve, Frenchtown, NJ) </del>was <del class="diffchange diffchange-inline">available as a reinforcer for every ten responses (FR10) on a designated injection appropriate lever. A houselight was centered over the hopper close </del>to the <del class="diffchange diffchange-inline">ceiling and was illuminated only when the levers were active. Each dose range included doses that were without effect to those producing at least 50% depression compared to vehicle control. Twenty-four male Sprague</del>-<del class="diffchange diffchange-inline">Dawley rats were obtained from Envigo (Houston, TX). Male ND4 Swiss–Webster mice were obtained from Envigo (Houston, TX) at approximately 8 weeks of age and maintained in the University of North Texas Health Science Center (UNTHSC) animal facility for two weeks prior to testin</del></div></td><td class='diff-marker'>+</td><td style="color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins class="diffchange diffchange-inline">Tremors were observed in mice 30 minutes following 1 mg/kg AMB-FUBINACA in the present study. Pretreatment times and dose ranges for the drug discrimination assay were selected based on the time of peak depression in the locomotor activity assay in mice. Average potency of the discriminative stimulus effects of early compounds was 0.81±0.17 mg/kg (Gatch et al., 2014), whereas the potency of a recent set was 0.09±0.03 mg/kg (Gatch et al., 2018), and the potency of the current set is 0.05±0.01 mg/kg. Short-onset, short-acting compounds have a greater abuse liability, and long-acting compounds pose problems of long-acting adverse effects and interactions with other drugs. The duration of action of the synthetic cannabinoids tested using the 8-h protocol have varied widely, with some producing a duration of action no longer than 1 h, others producing a duration of action between 1–2 h, and others lasting more than 2 h. There seems to be a trend of newer synthetic cannabinoids being more potent than earlier compound&lt;br&gt;&lt;br&gt;&lt;br&gt;Although there were reports on the metabolism of 4F-MDMB-BINACA using in-vivo and various in-vitro models, studies were either conducted using small in-vivo sample size such as 1 to 4 samples [5, 29] or in closed environments such as forensic psychiatric wards and prisons . The hepatic cell line HepG2 is often used as an initial screen as it is known to produce high reproducibility results with relatively stable enzyme concentration, although they are limited by the low-level expression of several metabolizing enzymes, including the cytochrome P450 (CYP) class of proteins [17, 18]. In-vitro metabolism studies are generally used to complement these data using perfused organs, tissue or cell cultures and microsomal preparations amongst which pooled human liver microsomes (HLM) have been frequently used to elucidate metabolism of SCBs [12,13,14,15,16]. Since most SCBs are found extensively in metabolized forms in urine, the identification of metabolites is of vital importance for forensic and clinical toxicologists. Identifying SCB intake and its correlating specific adverse effects require rapid elucidation of these SCBs. The proliferation of SCBs has become a global challenge as new compounds are rapidly introduced into the illegal drug market to evade existing drug law&lt;br&gt;&lt;br&gt;&lt;br&gt;Test 2 was performed everyday for 5 days after consecutive administration of the substances, including negative (vehicle) and positive (methamphetamine) controls. After the last administration, the first trial was performed. Morris water maze test was performed to evaluate the changes of learning and memory function through administration of the test substances. Generally, neurotoxicity of a substance is evaluated by animal behavioral aspects, i.e. functional observation battery (FOB) tests (O’Callaghan et al., 2014). Our results suggest that JWH-081 and JWH-210 may 4F ADB be neurotoxic substances through changing neuronal cell damages, especially in the core shell part of nucleus accumbens.&lt;br&gt;About Powder JWH-2&lt;br&gt;&lt;br&gt;&lt;br&gt;</ins>Locomotor activity in mice was tested to screen for locomotor depressant effects and to identify behaviorally-active dose ranges and times of peak effect. Previous studies have demonstrated that these compounds have chemical structures similar to synthetic cannabinoids known to have substantial abuse liability and act at the CB1 receptor. Tremors were not observed following AMB-FUBINACA during the drug discrimination study, but the maximum dose tested was only 0.1 mg/kg, which is 10-fold lower than the dose that produced tremors in the mice. AMB-FUBINACA has been implicated in severe adverse effects in recreational users (Adams et al., 2017; Hamilton et al., 2017), which suggests that the range between behaviorally active and toxic doses of AMB-FUBINACA is narrow. Following that line of reasoning, it should also be noted that some of the more recent compounds produced non-linear dose-effect curves and one compound produced an inverted U-shaped dose-effect, such that intermediate dose fully substituted, but higher doses did not (Gatch and Forster, 2018). All of the compounds identified as available on the recreational market and submitted to our laboratory by the US Drug Enforcement Agency for testing have fully substituted at some dose (Gatch and Forster 2014, 2015, 2016, 2018); however; it is important to note that not all structural congeners are active (Wiley et al., 2012&lt;br&gt;&lt;br&gt;&lt;br&gt;<ins class="diffchange diffchange-inline">LC-QTOF-MS represents a significant advancement in </ins>the <ins class="diffchange diffchange-inline">field of drug detection, offering higher sensitivity, specificity, and a broader spectrum </ins>of <ins class="diffchange diffchange-inline">detectable substances</ins>. <ins class="diffchange diffchange-inline">Despite all negative results in </ins>the <ins class="diffchange diffchange-inline">point</ins>-<ins class="diffchange diffchange-inline">of</ins>-<ins class="diffchange diffchange-inline">care test for recreational drugs</ins>, <ins class="diffchange diffchange-inline">the liquid chromatography-quadrupole time</ins>-of<ins class="diffchange diffchange-inline">-flight mass spectrometry </ins>(<ins class="diffchange diffchange-inline">LC-QTOF-MS</ins>) <ins class="diffchange diffchange-inline">analysis showed that the liquid of </ins>the <ins class="diffchange diffchange-inline">e</ins>-<ins class="diffchange diffchange-inline">cigarette contained ADB</ins>-<ins class="diffchange diffchange-inline">BUTINACA</ins>, <ins class="diffchange diffchange-inline">a synthetic cannabinoid. We report a 27-year-old man who was admitted to the emergency room because </ins>of <ins class="diffchange diffchange-inline">sudden </ins>[https://cannabinoidsrc4f-adb.com/ <ins class="diffchange diffchange-inline">4F ADB</ins>] <ins class="diffchange diffchange-inline">headache</ins>, <ins class="diffchange diffchange-inline">nausea</ins>, <ins class="diffchange diffchange-inline">vertigo</ins>, <ins class="diffchange diffchange-inline">red eyes </ins>and <ins class="diffchange diffchange-inline">palpitations</ins>. <ins class="diffchange diffchange-inline">Synthetic cannabinoids are gaining popularity globally </ins>and <ins class="diffchange diffchange-inline">detection </ins>is <ins class="diffchange diffchange-inline">not commonly available</ins>.&lt;br&gt;<ins class="diffchange diffchange-inline">Data availability </ins>&lt;br&gt;<ins class="diffchange diffchange-inline">When clinical presentation </ins>and<ins class="diffchange diffchange-inline">/or initial DOA testing results are inconclusive</ins>, <ins class="diffchange diffchange-inline">additional testing with LC</ins>-<ins class="diffchange diffchange-inline">QTOF</ins>-<ins class="diffchange diffchange-inline">MS can be valuable </ins>and <ins class="diffchange diffchange-inline">is recommended</ins>. <ins class="diffchange diffchange-inline">SCRAs </ins>and <ins class="diffchange diffchange-inline">other NPS may not be detected by point</ins>-<ins class="diffchange diffchange-inline">of</ins>-<ins class="diffchange diffchange-inline">care DOA tests</ins>. <ins class="diffchange diffchange-inline">In this case</ins>, the <ins class="diffchange diffchange-inline">point-</ins>of-<ins class="diffchange diffchange-inline">care DOA urine screening </ins>was <ins class="diffchange diffchange-inline">not able </ins>to <ins class="diffchange diffchange-inline">detect </ins>the <ins class="diffchange diffchange-inline">synthetic cannabinoid ADB</ins>-<ins class="diffchange diffchange-inline">BUTINAC</ins></div></td></tr> <!-- diff cache key stadtwiki:diff::1.12:old-34924:rev-34935 --> </table>

CaroleHoller04 https://www.stadtwiki-strausberg.de/index.php?title=5F-ADB_Wikipedia&diff=34924&oldid=prev 2026-06-21T18:35:28Z

<p></p> <table class="diff diff-contentalign-left" data-mw="interface"> <col class="diff-marker" /> <col class="diff-content" /> <col class="diff-marker" /> <col class="diff-content" /> <tr class="diff-title" lang="de"> <td colspan="2" style="background-color: #fff; color: #222; text-align: center;">← Nächstältere Version</td> <td colspan="2" style="background-color: #fff; color: #222; text-align: center;">Version vom 21. Juni 2026, 18:35 Uhr</td> </tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l1" >Zeile 1:</td> <td colspan="2" class="diff-lineno">Zeile 1:</td></tr> <tr><td class='diff-marker'>−</td><td style="color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del class="diffchange diffchange-inline">The </del>chemical structures <del class="diffchange diffchange-inline">of the recent </del>synthetic cannabinoids <del class="diffchange diffchange-inline">are unlike that of Δ9-THC, but are largely based on the structure of older synthetic cannabinoids that are </del>known to have substantial abuse liability <del class="diffchange diffchange-inline">(Fig</del>. 1<del class="diffchange diffchange-inline">&lt;br&gt;&lt;br&gt;&lt;br&gt;Demographic and clinical features are recorded and blood and</del>/<del class="diffchange diffchange-inline">or urine samples analysed using high</del>-<del class="diffchange diffchange-inline">resolution accurate mass liquid chromatography-mass spectrometry. The authors declare </del>that <del class="diffchange diffchange-inline">they have no known competing financial interests or personal relationships that could have appeared to influence </del>the <del class="diffchange diffchange-inline">work reported </del>in <del class="diffchange diffchange-inline">this paper</del>. <del class="diffchange diffchange-inline">Second</del>, <del class="diffchange diffchange-inline">we could not visit Cannabinoidsrc 4f Adb`s official website retrieve further detailed information about </del>the <del class="diffchange diffchange-inline">e</del>-<del class="diffchange diffchange-inline">cigarette </del>that <del class="diffchange diffchange-inline">was used by the patient such as the label or the region </del>of <del class="diffchange diffchange-inline">origin. Whether a recreational drug can </del>be <del class="diffchange diffchange-inline">administered via vaping, depends on whether the drug becomes volatile under the evaporation temperature </del>of the <del class="diffchange diffchange-inline">e</del>-<del class="diffchange diffchange-inline">cigarette. Of these samples, 22 contained </del>one <del class="diffchange diffchange-inline">or more SCRAs</del>, <del class="diffchange diffchange-inline">THC was only detected in 11 samples</del>, <del class="diffchange diffchange-inline">only one contained cannabidiol </del>and <del class="diffchange diffchange-inline">6 contained a mixture </del>of <del class="diffchange diffchange-inline">THC </del>and <del class="diffchange diffchange-inline">cannabidiol. There is difficulty in finding </del>the <del class="diffchange diffchange-inline">right information about the NPS</del>, <del class="diffchange diffchange-inline">defining their potency and confirmation of their existence in e-liquids or urine samples</del>.&lt;br&gt;<del class="diffchange diffchange-inline">Data availabili</del>&lt;br&gt;&lt;br&gt;<del class="diffchange diffchange-inline">&lt;br&gt;LC-QTOF-MS represents a significant advancement in </del>the <del class="diffchange diffchange-inline">field </del>of <del class="diffchange diffchange-inline">drug detection</del>, <del class="diffchange diffchange-inline">offering higher sensitivity, specificity, and a broader spectrum of detectable substances. Despite all negative results in </del>the <del class="diffchange diffchange-inline">point</del>-<del class="diffchange diffchange-inline">of</del>-<del class="diffchange diffchange-inline">care test for recreational drugs</del>, <del class="diffchange diffchange-inline">the liquid chromatography-quadrupole time</del>-of<del class="diffchange diffchange-inline">-flight mass spectrometry </del>(<del class="diffchange diffchange-inline">LC-QTOF-MS</del>) <del class="diffchange diffchange-inline">analysis showed that the liquid of </del>the <del class="diffchange diffchange-inline">e</del>-<del class="diffchange diffchange-inline">cigarette contained ADB</del>-<del class="diffchange diffchange-inline">BUTINACA</del>, <del class="diffchange diffchange-inline">a synthetic cannabinoid. We report a 27-year-old man who was admitted to the emergency room because </del>of <del class="diffchange diffchange-inline">sudden </del>[https://cannabinoidsrc4f-adb.com/ <del class="diffchange diffchange-inline">visit Cannabinoidsrc 4f Adb`s official website</del>] <del class="diffchange diffchange-inline">Cannabinoidsrc 4f Adb`s official website headache, nausea, vertigo, red eyes and palpitations. Synthetic cannabinoids are gaining popularity globally and detection is not commonly availabl</del>&lt;br&gt;&lt;br&gt;&lt;br&gt;<del class="diffchange diffchange-inline">High resolution mass spectrometry such </del>as <del class="diffchange diffchange-inline">LC</del>-<del class="diffchange diffchange-inline">QTOF-MS allows the detection </del>and <del class="diffchange diffchange-inline">identification of </del>a <del class="diffchange diffchange-inline">broad spectrum of recreational drugs</del>, <del class="diffchange diffchange-inline">including new psychoactive substances. A point-</del>of-<del class="diffchange diffchange-inline">care drugs of abuse (DOA) test was initially performed on the urine of the patient</del>. <del class="diffchange diffchange-inline">He confirmed drinking 750 ml energy drink without any further consumption of food and using </del>an <del class="diffchange diffchange-inline">e-cigarette from Gaziantep, Turkey 10 seconds before the onset of his first symptoms. He usually smokes a pack of cigarettes a day </del>and <del class="diffchange diffchange-inline">sometimes smokes e-cigarettes. Combined </del>with <del class="diffchange diffchange-inline">non-specific, transient symptoms, clinical recognition of SCRA intoxication is challenging </del>.&lt;br&gt;<del class="diffchange diffchange-inline">Data availability </del>&lt;br&gt;<del class="diffchange diffchange-inline">The intensity </del>is <del class="diffchange diffchange-inline">plotted against the retention time </del>for <del class="diffchange diffchange-inline">both chromatograms</del>, <del class="diffchange diffchange-inline">demonstrating the visit Cannabinoidsrc 4f Adb`s official website presence and elution profiles of nicotine and ADB</del>-<del class="diffchange diffchange-inline">BUTINACA in the analysed vape liquid sample</del>. <del class="diffchange diffchange-inline">LC</del>-<del class="diffchange diffchange-inline">QTOF</del>-<del class="diffchange diffchange-inline">MS Chromatograms </del>of <del class="diffchange diffchange-inline">Nicotine (Top) </del>and <del class="diffchange diffchange-inline">ADB-BUTINACA (Bottom) in the Vape Liquid used by the patient</del>. <del class="diffchange diffchange-inline">The LC</del>-<del class="diffchange diffchange-inline">QTOF-MS analysis showed that the e-liquid contained nicotine </del>and <del class="diffchange diffchange-inline">ADB-BUTINACA (Fig</del>. <del class="diffchange diffchange-inline">1). Because the point-of-care DOA test is generally not able to detect synthetic recreational drug substances</del>, <del class="diffchange diffchange-inline">the liquid of the e</del>-<del class="diffchange diffchange-inline">cigarette was thereafter screened using liquid chromatography-quadrupole time-of-flight mass spectrometry (LC-QTOF-MS) on the Waters™ Xevo G3 QTOF MS system. After eating </del>a <del class="diffchange diffchange-inline">light meal </del>and <del class="diffchange diffchange-inline">drinking caffeinated sports drinks at the ER</del>, <del class="diffchange diffchange-inline">the nausea complaints of the patient were reduced </del>and <del class="diffchange diffchange-inline">the patient was discharged hom&lt;br&gt;</del>&lt;br&gt;&lt;br&gt;A <del class="diffchange diffchange-inline">limitation </del>of <del class="diffchange diffchange-inline">this case report is that we did not have a urine sample available for additional NPS testing. Point-of-care DOA tests using urine to screen for misuse of multiple substances, regularly include cannabis, amphetamines, cocaine, opioids</del>, <del class="diffchange diffchange-inline">benzodiazepines and methadone</del>. <del class="diffchange diffchange-inline">THC</del>, methamphetamine, <del class="diffchange diffchange-inline">SRCA</del>, <del class="diffchange diffchange-inline">lysergic acid diethylamide (LSD</del>), <del class="diffchange diffchange-inline">gamma-hydroxybutyrate (GHB) and ketamine are likely to become volatile under the temperature </del>of <del class="diffchange diffchange-inline">current e-cigarettes, while crack cocaine is hard to vaporise</del>. <del class="diffchange diffchange-inline">A systematic review including data </del>of <del class="diffchange diffchange-inline">114 patients of which </del>the <del class="diffchange diffchange-inline">majority was intoxicated due to SCRA smoking revealed that 45 % </del>of the <del class="diffchange diffchange-inline">patients who present at </del>the <del class="diffchange diffchange-inline">ER after an intoxication due to SCRA smoking recovered within 24 hours</del>&lt;br&gt;&lt;br&gt;<del class="diffchange diffchange-inline">&lt;br&gt;In the present study, we performed various methods based on animal behavioral testing including FOB </del>test for <del class="diffchange diffchange-inline">general behavioral observation, rotarod </del>test<del class="diffchange diffchange-inline">, </del>locomotor activity <del class="diffchange diffchange-inline">test for motor function evaluation</del>, <del class="diffchange diffchange-inline">and water-maze test for learning/memory evaluation. Known for its stability and consistent composition</del>, <del class="diffchange diffchange-inline">this compound is frequently utilized by professionals seeking reliable materials for laboratory-based analytical studies. In this study</del>, <del class="diffchange diffchange-inline">histopathological evaluation was performed to confirm </del>the <del class="diffchange diffchange-inline">possibility of neurotoxicity </del>of the <del class="diffchange diffchange-inline">tested substances by hematoxylin and eosin staining method from collected brain samples</del>. <del class="diffchange diffchange-inline">In </del>the <del class="diffchange diffchange-inline">present study</del>, <del class="diffchange diffchange-inline">we evaluated the neurotoxicity </del>of <del class="diffchange diffchange-inline">two synthetic cannabinoids (JWH</del>-<del class="diffchange diffchange-inline">081 </del>and <del class="diffchange diffchange-inline">JWH</del>-<del class="diffchange diffchange-inline">210) through observation of various behavioral changes and analysis of histopathological changes using experimental mice with various doses </del>(<del class="diffchange diffchange-inline">0.1</del>, <del class="diffchange diffchange-inline">1</del>, <del class="diffchange diffchange-inline">5 mg/kg</del>). <del class="diffchange diffchange-inline">Selecting powder JWH-210 demands careful evaluation of purity, legality, </del>and <del class="diffchange diffchange-inline">supplier credibility</del>. <del class="diffchange diffchange-inline">Prices for research</del>-<del class="diffchange diffchange-inline">grade JWH</del>-<del class="diffchange diffchange-inline">210 vary significantly based on quantity</del>, <del class="diffchange diffchange-inline">purity</del>, and <del class="diffchange diffchange-inline">vendor complianc</del></div></td><td class='diff-marker'>+</td><td style="color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins class="diffchange diffchange-inline">Locomotor activity in mice was tested to screen for locomotor depressant effects and to identify behaviorally-active dose ranges and times of peak effect. Previous studies have demonstrated that these compounds have </ins>chemical structures <ins class="diffchange diffchange-inline">similar to </ins>synthetic cannabinoids known to have substantial abuse liability <ins class="diffchange diffchange-inline">and act at the CB1 receptor. Tremors were not observed following AMB-FUBINACA during the drug discrimination study, but the maximum dose tested was only 0</ins>.1 <ins class="diffchange diffchange-inline">mg</ins>/<ins class="diffchange diffchange-inline">kg, which is 10</ins>-<ins class="diffchange diffchange-inline">fold lower than the dose </ins>that <ins class="diffchange diffchange-inline">produced tremors in </ins>the <ins class="diffchange diffchange-inline">mice. AMB-FUBINACA has been implicated in severe adverse effects </ins>in <ins class="diffchange diffchange-inline">recreational users (Adams et al</ins>., <ins class="diffchange diffchange-inline">2017; Hamilton et al., 2017), which suggests that </ins>the <ins class="diffchange diffchange-inline">range between behaviorally active and toxic doses of AMB</ins>-<ins class="diffchange diffchange-inline">FUBINACA is narrow. Following </ins>that <ins class="diffchange diffchange-inline">line </ins>of <ins class="diffchange diffchange-inline">reasoning, it should also </ins>be <ins class="diffchange diffchange-inline">noted that some </ins>of the <ins class="diffchange diffchange-inline">more recent compounds produced non</ins>-<ins class="diffchange diffchange-inline">linear dose-effect curves and </ins>one <ins class="diffchange diffchange-inline">compound produced an inverted U-shaped dose-effect</ins>, <ins class="diffchange diffchange-inline">such that intermediate dose fully substituted</ins>, <ins class="diffchange diffchange-inline">but higher doses did not (Gatch </ins>and <ins class="diffchange diffchange-inline">Forster, 2018). All </ins>of <ins class="diffchange diffchange-inline">the compounds identified as available on the recreational market </ins>and <ins class="diffchange diffchange-inline">submitted to our laboratory by </ins>the <ins class="diffchange diffchange-inline">US Drug Enforcement Agency for testing have fully substituted at some dose (Gatch and Forster 2014, 2015, 2016</ins>, <ins class="diffchange diffchange-inline">2018); however; it is important to note that not all structural congeners are active (Wiley et al</ins>.<ins class="diffchange diffchange-inline">, 2012</ins>&lt;br&gt;&lt;br&gt;&lt;br&gt;<ins class="diffchange diffchange-inline">Taken together these data further confirmed </ins>the <ins class="diffchange diffchange-inline">structure elucidation </ins>of <ins class="diffchange diffchange-inline">B16. The precursor ion m/z 276 (B1) detected</ins>, <ins class="diffchange diffchange-inline">which was 74 Da lower than that for </ins>the <ins class="diffchange diffchange-inline">4F</ins>-<ins class="diffchange diffchange-inline">MDMB</ins>-<ins class="diffchange diffchange-inline">BINACA ester hydrolysis metabolite (B22)</ins>, <ins class="diffchange diffchange-inline">indicated N</ins>-<ins class="diffchange diffchange-inline">dealkylation </ins>of <ins class="diffchange diffchange-inline">B22. The precursor ion m/z 348 and product ion detected at m/z 217 </ins>(<ins class="diffchange diffchange-inline">B2</ins>) <ins class="diffchange diffchange-inline">identified was 2 Da less than </ins>the <ins class="diffchange diffchange-inline">4F</ins>-<ins class="diffchange diffchange-inline">MDMB</ins>-<ins class="diffchange diffchange-inline">BINACA ester hydrolysis metabolite (B22)</ins>, <ins class="diffchange diffchange-inline">indicating oxidative defluorination (loss of fluorine with addition </ins>of <ins class="diffchange diffchange-inline">hydroxy </ins>[https://cannabinoidsrc4f-adb.com/ <ins class="diffchange diffchange-inline">5CL ADBA powder</ins>] <ins class="diffchange diffchange-inline">group</ins>&lt;br&gt;&lt;br&gt;&lt;br&gt;<ins class="diffchange diffchange-inline">In summary, JWH-210 Chemical Powder stands out </ins>as <ins class="diffchange diffchange-inline">a high</ins>-<ins class="diffchange diffchange-inline">quality research compound designed for professionals who demand accuracy, consistency, </ins>and <ins class="diffchange diffchange-inline">reliability. This commitment to 5CL ADBA powder quality makes it </ins>a <ins class="diffchange diffchange-inline">trusted option for professionals who require dependable compounds for their work. From sourcing raw materials to final packaging</ins>, <ins class="diffchange diffchange-inline">every stage </ins>of <ins class="diffchange diffchange-inline">the process is monitored to ensure compliance with laboratory</ins>-<ins class="diffchange diffchange-inline">grade expectations</ins>. <ins class="diffchange diffchange-inline">This makes it </ins>an <ins class="diffchange diffchange-inline">ideal choice for laboratories that prioritize both efficiency </ins>and <ins class="diffchange diffchange-inline">compliance </ins>with <ins class="diffchange diffchange-inline">research standards</ins>.&lt;br&gt;<ins class="diffchange diffchange-inline">Key Features and Specifications to Evaluate </ins>&lt;br&gt;<ins class="diffchange diffchange-inline">Higher prices often reflect rigorous quality control rather than markup alone. This compound </ins>is <ins class="diffchange diffchange-inline">appropriate only </ins>for <ins class="diffchange diffchange-inline">authorized professionals conducting lawful research or analysis. For legitimate applications, only fully characterized</ins>, <ins class="diffchange diffchange-inline">independently tested JWH</ins>-<ins class="diffchange diffchange-inline">210 5CL ADBA powder should be considered</ins>.<ins class="diffchange diffchange-inline">&lt;br&gt;How to Choose Powder JWH</ins>-<ins class="diffchange diffchange-inline">210 &lt;br&gt;This dual</ins>-<ins class="diffchange diffchange-inline">use nature underscores the importance </ins>of <ins class="diffchange diffchange-inline">responsible sourcing </ins>and <ins class="diffchange diffchange-inline">strict adherence to legal frameworks</ins>. <ins class="diffchange diffchange-inline">Forensic labs, public health researchers, and customs officials use authentic samples like JWH</ins>-<ins class="diffchange diffchange-inline">210 to distinguish between legal </ins>and <ins class="diffchange diffchange-inline">illegal compounds in seized materials</ins>. <ins class="diffchange diffchange-inline">For those seeking a dependable compound for analytical purposes</ins>, <ins class="diffchange diffchange-inline">JWH</ins>-<ins class="diffchange diffchange-inline">210 Chemical Powder provides </ins>a <ins class="diffchange diffchange-inline">trusted </ins>and <ins class="diffchange diffchange-inline">effective solution. With its carefully controlled production process, stable composition</ins>, and <ins class="diffchange diffchange-inline">secure packaging, it remains a valuable resource for laboratory-based research.</ins>&lt;br&gt;<ins class="diffchange diffchange-inline">Is JWH-210 Legal? </ins>&lt;br&gt;A <ins class="diffchange diffchange-inline">total </ins>of <ins class="diffchange diffchange-inline">2 and 3 methamphetamine treated mice fell from the spinning rod 30 min and 2 hr after the administration</ins>, <ins class="diffchange diffchange-inline">respectively</ins>. <ins class="diffchange diffchange-inline">After the first injection</ins>, <ins class="diffchange diffchange-inline">6 mice of the positive control group (</ins>methamphetamine, <ins class="diffchange diffchange-inline">5 mg/kg</ins>, <ins class="diffchange diffchange-inline">i.p.</ins>) <ins class="diffchange diffchange-inline">showed loss of traction</ins>, of <ins class="diffchange diffchange-inline">which 4 showed tremor</ins>. <ins class="diffchange diffchange-inline">Most </ins>of the <ins class="diffchange diffchange-inline">abnormalities were normalized in synthetic cannabinoid treated mice although those abnormal behaviors remained in methamphetamine treated animals after 2 hr </ins>of <ins class="diffchange diffchange-inline">administration. Brain samples were prepared from </ins>the <ins class="diffchange diffchange-inline">mice after </ins>the <ins class="diffchange diffchange-inline">last administration of test substance</ins>&lt;br&gt;&lt;br&gt;<ins class="diffchange diffchange-inline">The </ins>test <ins class="diffchange diffchange-inline">apparatus </ins>for <ins class="diffchange diffchange-inline">the locomotor activity </ins>test <ins class="diffchange diffchange-inline">was designed to measure </ins>locomotor activity <ins class="diffchange diffchange-inline">automatically using UV system (AM 1051</ins>, <ins class="diffchange diffchange-inline">Benwick Electronics</ins>, <ins class="diffchange diffchange-inline">Benwick</ins>, <ins class="diffchange diffchange-inline">UK) when experimental animals moved in </ins>the <ins class="diffchange diffchange-inline">chambe&lt;br&gt;&lt;br&gt;Figure 1. &lt;br&gt;Each training session lasted a maximum </ins>of <ins class="diffchange diffchange-inline">10 min, and </ins>the <ins class="diffchange diffchange-inline">rats could earn up to 20 food pellets</ins>. <ins class="diffchange diffchange-inline">Thirty minutes prior to </ins>the <ins class="diffchange diffchange-inline">training sessions</ins>, <ins class="diffchange diffchange-inline">rats received an injection </ins>of <ins class="diffchange diffchange-inline">either vehicle or Δ9</ins>-<ins class="diffchange diffchange-inline">THC </ins>and <ins class="diffchange diffchange-inline">were subsequently placed in the behavior</ins>-<ins class="diffchange diffchange-inline">testing chambers, where food </ins>(<ins class="diffchange diffchange-inline">45-mg food pellets; Bio-Serve</ins>, <ins class="diffchange diffchange-inline">Frenchtown</ins>, <ins class="diffchange diffchange-inline">NJ) was available as a reinforcer for every ten responses (FR10</ins>) <ins class="diffchange diffchange-inline">on a designated injection appropriate lever</ins>. <ins class="diffchange diffchange-inline">A houselight was centered over the hopper close to the ceiling </ins>and <ins class="diffchange diffchange-inline">was illuminated only when the levers were active. Each dose range included doses that were without effect to those producing at least 50% depression compared to vehicle control</ins>. <ins class="diffchange diffchange-inline">Twenty</ins>-<ins class="diffchange diffchange-inline">four male Sprague</ins>-<ins class="diffchange diffchange-inline">Dawley rats were obtained from Envigo (Houston</ins>, <ins class="diffchange diffchange-inline">TX). Male ND4 Swiss–Webster mice were obtained from Envigo (Houston</ins>, <ins class="diffchange diffchange-inline">TX) at approximately 8 weeks of age </ins>and <ins class="diffchange diffchange-inline">maintained in the University of North Texas Health Science Center (UNTHSC) animal facility for two weeks prior to testin</ins></div></td></tr> <!-- diff cache key stadtwiki:diff::1.12:old-34922:rev-34924 --> </table>

ScarlettCagle66 https://www.stadtwiki-strausberg.de/index.php?title=5F-ADB_Wikipedia&diff=34922&oldid=prev 2026-06-21T18:33:04Z

<p></p> <table class="diff diff-contentalign-left" data-mw="interface"> <col class="diff-marker" /> <col class="diff-content" /> <col class="diff-marker" /> <col class="diff-content" /> <tr class="diff-title" lang="de"> <td colspan="2" style="background-color: #fff; color: #222; text-align: center;">← Nächstältere Version</td> <td colspan="2" style="background-color: #fff; color: #222; text-align: center;">Version vom 21. Juni 2026, 18:33 Uhr</td> </tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l1" >Zeile 1:</td> <td colspan="2" class="diff-lineno">Zeile 1:</td></tr> <tr><td class='diff-marker'>−</td><td style="color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del class="diffchange diffchange-inline">Tremors were not observed following AMB</del>-<del class="diffchange diffchange-inline">FUBINACA during the drug discrimination study</del>, but the <del class="diffchange diffchange-inline">maximum dose tested was only 0</del>.1 <del class="diffchange diffchange-inline">mg/kg, which is 10-fold lower than the dose that produced tremors in the mic</del>&lt;br&gt;&lt;br&gt;&lt;br&gt;<del class="diffchange diffchange-inline">A 30</del>-<del class="diffchange diffchange-inline">min period, beginning when maximal depression of locomotor activity first appeared as a function of dose, was used for analysis of dose</del>-<del class="diffchange diffchange-inline">response data and calculation of ED50 values</del>. <del class="diffchange diffchange-inline">During test sessions, both levers were active, such </del>that <del class="diffchange diffchange-inline">ten consecutive responses on either lever led </del>to <del class="diffchange diffchange-inline">[https://cannabinoidsrc4f-adb</del>.<del class="diffchange diffchange-inline">com/ https://cannabinoidsrc4f-adb.com/] reinforcement. The substitution tests occurred only if </del>the <del class="diffchange diffchange-inline">rats had achieved 85% injection</del>-<del class="diffchange diffchange-inline">appropriate responding on the two prior training sessions.&lt;br&gt;The locomotor activity assay </del>was used <del class="diffchange diffchange-inline">to identify approximate time courses and dose ranges </del>of <del class="diffchange diffchange-inline">psychoactive effects</del>, <del class="diffchange diffchange-inline">which is useful for identifying parameters for </del>drug <del class="diffchange diffchange-inline">discrimination experiments and are also predictive of </del>the <del class="diffchange diffchange-inline">time course </del>of the <del class="diffchange diffchange-inline">psychoactive effects in human users</del>. <del class="diffchange diffchange-inline">The purpose of the present study was to assess the abuse liability of 5F-MDMB-PINACA</del>, <del class="diffchange diffchange-inline">MDMB-CHIMICA</del>, <del class="diffchange diffchange-inline">MDMB-FUBINACA, ADB-FUBINACA</del>, and <del class="diffchange diffchange-inline">AMB-FUBINACA</del>. <del class="diffchange diffchange-inline">Since there </del>is <del class="diffchange diffchange-inline">currently no robust measure of </del>the <del class="diffchange diffchange-inline">reinforcing/rewarding effects of cannabinoids, drug discrimination is currently </del>the <del class="diffchange diffchange-inline">best model for assessing abuse liability of cannabinoids. The findings produce an apparent paradox</del>, <del class="diffchange diffchange-inline">since CPP </del>and <del class="diffchange diffchange-inline">self</del>-<del class="diffchange diffchange-inline">administration predict with high reliability the likelihood that a compound will be abused by humans, and cannabinoids are well-known to produce active drug-seeking in human</del>&lt;br&gt;&lt;br&gt;<del class="diffchange diffchange-inline">4. Drugs </del>&lt;br&gt;<del class="diffchange diffchange-inline">In general, </del>the <del class="diffchange diffchange-inline">locomotor depressant and discriminative stimulus effects have been observed at doses that do not produce adverse effects</del>, <del class="diffchange diffchange-inline">although tremors were observed upon handling in mice that received JWH-210 (Gatch et al.</del>, <del class="diffchange diffchange-inline">2016)</del>, and <del class="diffchange diffchange-inline">5F-AMB produced sustained vocalization and convulsions in rats (Gatch et al</del>.<del class="diffchange diffchange-inline">, 2018). All of the synthetic cannabinoids tested </del>in the <del class="diffchange diffchange-inline">present study fully substituted </del>for the <del class="diffchange diffchange-inline">discriminative stimulus effects </del>of <del class="diffchange diffchange-inline">Δ9</del>-<del class="diffchange diffchange-inline">THC. Subsequently, a one</del>-<del class="diffchange diffchange-inline">way </del>analysis <del class="diffchange diffchange-inline">of variance was conducted on horizontal activity counts for </del>the <del class="diffchange diffchange-inline">30-min period </del>of <del class="diffchange diffchange-inline">maximal effect, and planned comparisons were conducted for each dose against </del>the <del class="diffchange diffchange-inline">vehicle control using single degree</del>-<del class="diffchange diffchange-inline">of</del>-<del class="diffchange diffchange-inline">freedom F tests. A two-way analysis of variance</del>, <del class="diffchange diffchange-inline">with dose as </del>a <del class="diffchange diffchange-inline">between groups factor and time as </del>a <del class="diffchange diffchange-inline">within subject factor, </del>was <del class="diffchange diffchange-inline">conducted on horizontal activity counts</del>/<del class="diffchange diffchange-inline">10 min interval</del>. <del class="diffchange diffchange-inline">Locomotor activity in mice was tested to screen for locomotor depressant effects </del>and <del class="diffchange diffchange-inline">to identify behaviorally-active dose ranges and times of peak effect</del>. <del class="diffchange diffchange-inline">Previous studies have demonstrated that these compounds have chemical structures similar to synthetic </del>cannabinoids <del class="diffchange diffchange-inline">known to have substantial abuse liability </del>and <del class="diffchange diffchange-inline">act at the CB1 receptor.</del>&lt;br&gt;<del class="diffchange diffchange-inline">Michael B Gatch </del>&lt;br&gt;<del class="diffchange diffchange-inline">Substantial depressant effects were observed within </del>the <del class="diffchange diffchange-inline">first 10 min</del>, <del class="diffchange diffchange-inline">and maximal depression was observed between 0–30 min following administration</del>. <del class="diffchange diffchange-inline">Tremors were observed 30 minutes following 1 mg/kg AMB</del>-<del class="diffchange diffchange-inline">FUBINACA in 3 </del>of <del class="diffchange diffchange-inline">8 mice </del>(<del class="diffchange diffchange-inline">data not shown</del>). <del class="diffchange diffchange-inline">Substantial depressant effects were observed within </del>the first <del class="diffchange diffchange-inline">10 min, </del>and <del class="diffchange diffchange-inline">maximal depression was observed between 10–40 min and lasted up to 2</del>.<del class="diffchange diffchange-inline">5 to 3 h at the https://cannabinoidsrc4f</del>-<del class="diffchange diffchange-inline">adb.com/ highest dose tested (0.5 mg/kg)</del>.&lt;br&gt;<del class="diffchange diffchange-inline">Figure 1. </del>&lt;br&gt;<del class="diffchange diffchange-inline">There </del>is <del class="diffchange diffchange-inline">indication that at least some </del>of the <del class="diffchange diffchange-inline">first</del>-<del class="diffchange diffchange-inline">generation synthetic cannabinoids act at receptors other than cannabinoid CB1 and CB2 </del>(<del class="diffchange diffchange-inline">Wiley et al., 2016</del>)<del class="diffchange diffchange-inline">, </del>and <del class="diffchange diffchange-inline">a compound from the present study, 5F-MDMB</del>-<del class="diffchange diffchange-inline">PINACA, was found to activate midbrain dopamine neurons, but not serotonin neurons </del>(<del class="diffchange diffchange-inline">Asaoka et al., 2016</del>)<del class="diffchange diffchange-inline">. As previously mentioned, all of </del>the <del class="diffchange diffchange-inline">compounds tested in </del>the <del class="diffchange diffchange-inline">present study (MDMB</del>-<del class="diffchange diffchange-inline">PINACA, MDMB</del>-<del class="diffchange diffchange-inline">CHMICA, MDMB</del>-<del class="diffchange diffchange-inline">FUBINACA, </del>ADB-<del class="diffchange diffchange-inline">FUBINACA, and AMB-FUBINACA) act as agonists at CB1 receptors </del>(<del class="diffchange diffchange-inline">Banister et al</del>.<del class="diffchange diffchange-inline">, 2015, 2016; Gamage et al</del>.<del class="diffchange diffchange-inline">, 2018), which suggests these compounds will produce Δ9</del>-<del class="diffchange diffchange-inline">THC</del>-<del class="diffchange diffchange-inline">like effects, including abuse liability. Tremors were </del>not <del class="diffchange diffchange-inline">observed following AMB-FUBINACA during the </del>drug <del class="diffchange diffchange-inline">discrimination study</del>, <del class="diffchange diffchange-inline">but </del>the <del class="diffchange diffchange-inline">maximum dose tested </del>was <del class="diffchange diffchange-inline">only 0</del>.<del class="diffchange diffchange-inline">1 mg/kg</del>, <del class="diffchange diffchange-inline">which is 10-fold lower than </del>the <del class="diffchange diffchange-inline">dose that produced tremors in </del>the <del class="diffchange diffchange-inline">mice.</del>&lt;br&gt;<del class="diffchange diffchange-inline">Michael B Gat</del>&lt;br&gt;&lt;br&gt;<del class="diffchange diffchange-inline">&lt;br&gt;These synthetic cannabinoids act directly at cannabinoid CB1 and CB2 receptors as does Δ9</del>-<del class="diffchange diffchange-inline">tetrahydrocannabinol (Δ9</del>-<del class="diffchange diffchange-inline">THC) found in marijuana</del>, <del class="diffchange diffchange-inline">but have different chemical structures unrelated to Δ9-THC</del>, <del class="diffchange diffchange-inline">different metabolism</del>, and <del class="diffchange diffchange-inline">often greater toxicity (Fantegrossi et al</del>., <del class="diffchange diffchange-inline">2014</del>)<del class="diffchange diffchange-inline">. Discriminative stimulus effects were tested in rats trained to discriminate Δ9-tetrahydrocannabinol (3 mg/kg</del>, <del class="diffchange diffchange-inline">30-min pretreatment). 5F-MDMB</del>-<del class="diffchange diffchange-inline">PINACA </del>(<del class="diffchange diffchange-inline">also known as 5F-ADB, 5F-ADB-PINACA</del>)<del class="diffchange diffchange-inline">, MDMB-CHIMICA, MDMB-FUBINACA, ADB-FUBINACA, </del>and <del class="diffchange diffchange-inline">AMB-FUBINACA (also known as FUB</del>-<del class="diffchange diffchange-inline">AMB</del>, <del class="diffchange diffchange-inline">MMB-FUBINACA) were tested for in vivo cannabinoid-like effects </del>to <del class="diffchange diffchange-inline">assess their abuse liabilit</del>&lt;br&gt;&lt;br&gt;&lt;br&gt;<del class="diffchange diffchange-inline">LC separates </del>the <del class="diffchange diffchange-inline">urine or blood sample </del>and <del class="diffchange diffchange-inline">QTOF</del>-<del class="diffchange diffchange-inline">MS provides high-resolution and accurate mass measurements </del>for <del class="diffchange diffchange-inline">precise identification and structural elucidation of compounds</del>. <del class="diffchange diffchange-inline">The LC-QTOF-MS method offers a more comprehensive </del>and <del class="diffchange diffchange-inline">sensitive approach </del>for <del class="diffchange diffchange-inline">drug detection</del>, <del class="diffchange diffchange-inline">covering hundreds </del>of <del class="diffchange diffchange-inline">recreational drugs, including NPS</del>. <del class="diffchange diffchange-inline">Besides increasing </del>the <del class="diffchange diffchange-inline">temperature to enlarge the drug aerolisation and bioavailability</del>, <del class="diffchange diffchange-inline">one can elevate </del>the <del class="diffchange diffchange-inline">flow rate </del>of <del class="diffchange diffchange-inline">air </del>through <del class="diffchange diffchange-inline">the e-cigarette </del>and/<del class="diffchange diffchange-inline">or add a diluent </del>. <del class="diffchange diffchange-inline">Of all e</del>-<del class="diffchange diffchange-inline">cigarette users registered at this forum</del>, <del class="diffchange diffchange-inline">7.8 % vaped SCRAs </del>. <del class="diffchange diffchange-inline">About 15 % of individuals registered at forums </del>for <del class="diffchange diffchange-inline">drug users such as erowid.org who vaped cannabis have also vaped SRCAs. SCRAs belong</del>, <del class="diffchange diffchange-inline">together with synthetic opioids, cathinones</del>, <del class="diffchange diffchange-inline">amphetamines </del>and <del class="diffchange diffchange-inline">hallucinogens to the new psychoactive substances (NPS) that are currently developed at high speed.&lt;br&gt;Data availabili</del></div></td><td class='diff-marker'>+</td><td style="color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins class="diffchange diffchange-inline">The chemical structures of the recent synthetic cannabinoids are unlike that of Δ9</ins>-<ins class="diffchange diffchange-inline">THC</ins>, but <ins class="diffchange diffchange-inline">are largely based on </ins>the <ins class="diffchange diffchange-inline">structure of older synthetic cannabinoids that are known to have substantial abuse liability (Fig</ins>. 1&lt;br&gt;&lt;br&gt;&lt;br&gt;<ins class="diffchange diffchange-inline">Demographic and clinical features are recorded and blood and/or urine samples analysed using high</ins>-<ins class="diffchange diffchange-inline">resolution accurate mass liquid chromatography</ins>-<ins class="diffchange diffchange-inline">mass spectrometry</ins>. <ins class="diffchange diffchange-inline">The authors declare that they have no known competing financial interests or personal relationships </ins>that <ins class="diffchange diffchange-inline">could have appeared </ins>to <ins class="diffchange diffchange-inline">influence the work reported in this paper</ins>. <ins class="diffchange diffchange-inline">Second, we could not visit Cannabinoidsrc 4f Adb`s official website retrieve further detailed information about </ins>the <ins class="diffchange diffchange-inline">e</ins>-<ins class="diffchange diffchange-inline">cigarette that </ins>was used <ins class="diffchange diffchange-inline">by the patient such as the label or the region </ins>of <ins class="diffchange diffchange-inline">origin. Whether a recreational drug can be administered via vaping</ins>, <ins class="diffchange diffchange-inline">depends on whether the </ins>drug <ins class="diffchange diffchange-inline">becomes volatile under </ins>the <ins class="diffchange diffchange-inline">evaporation temperature </ins>of the <ins class="diffchange diffchange-inline">e-cigarette</ins>. <ins class="diffchange diffchange-inline">Of these samples</ins>, <ins class="diffchange diffchange-inline">22 contained one or more SCRAs</ins>, <ins class="diffchange diffchange-inline">THC was only detected in 11 samples</ins>, <ins class="diffchange diffchange-inline">only one contained cannabidiol and 6 contained a mixture of THC </ins>and <ins class="diffchange diffchange-inline">cannabidiol</ins>. <ins class="diffchange diffchange-inline">There </ins>is <ins class="diffchange diffchange-inline">difficulty in finding </ins>the <ins class="diffchange diffchange-inline">right information about </ins>the <ins class="diffchange diffchange-inline">NPS</ins>, <ins class="diffchange diffchange-inline">defining their potency </ins>and <ins class="diffchange diffchange-inline">confirmation of their existence in e</ins>-<ins class="diffchange diffchange-inline">liquids or urine samples.&lt;br&gt;Data availabili</ins>&lt;br&gt;&lt;br&gt;&lt;br&gt;<ins class="diffchange diffchange-inline">LC-QTOF-MS represents a significant advancement in </ins>the <ins class="diffchange diffchange-inline">field of drug detection</ins>, <ins class="diffchange diffchange-inline">offering higher sensitivity</ins>, <ins class="diffchange diffchange-inline">specificity</ins>, and <ins class="diffchange diffchange-inline">a broader spectrum of detectable substances</ins>. <ins class="diffchange diffchange-inline">Despite all negative results </ins>in the <ins class="diffchange diffchange-inline">point-of-care test </ins>for <ins class="diffchange diffchange-inline">recreational drugs, </ins>the <ins class="diffchange diffchange-inline">liquid chromatography-quadrupole time-</ins>of-<ins class="diffchange diffchange-inline">flight mass spectrometry (LC-QTOF</ins>-<ins class="diffchange diffchange-inline">MS) </ins>analysis <ins class="diffchange diffchange-inline">showed that </ins>the <ins class="diffchange diffchange-inline">liquid </ins>of the <ins class="diffchange diffchange-inline">e</ins>-<ins class="diffchange diffchange-inline">cigarette contained ADB</ins>-<ins class="diffchange diffchange-inline">BUTINACA</ins>, a <ins class="diffchange diffchange-inline">synthetic cannabinoid. We report </ins>a <ins class="diffchange diffchange-inline">27-year-old man who </ins>was <ins class="diffchange diffchange-inline">admitted to the emergency room because of sudden [https:/</ins>/<ins class="diffchange diffchange-inline">cannabinoidsrc4f-adb</ins>.<ins class="diffchange diffchange-inline">com/ visit Cannabinoidsrc 4f Adb`s official website] Cannabinoidsrc 4f Adb`s official website headache, nausea, vertigo, red eyes </ins>and <ins class="diffchange diffchange-inline">palpitations</ins>. <ins class="diffchange diffchange-inline">Synthetic </ins>cannabinoids <ins class="diffchange diffchange-inline">are gaining popularity globally </ins>and <ins class="diffchange diffchange-inline">detection is not commonly availabl&lt;br&gt;</ins>&lt;br&gt;&lt;br&gt;<ins class="diffchange diffchange-inline">High resolution mass spectrometry such as LC-QTOF-MS allows </ins>the <ins class="diffchange diffchange-inline">detection and identification of a broad spectrum of recreational drugs</ins>, <ins class="diffchange diffchange-inline">including new psychoactive substances</ins>. <ins class="diffchange diffchange-inline">A point-of</ins>-<ins class="diffchange diffchange-inline">care drugs </ins>of <ins class="diffchange diffchange-inline">abuse </ins>(<ins class="diffchange diffchange-inline">DOA</ins>) <ins class="diffchange diffchange-inline">test was initially performed on the urine of the patient</ins>. <ins class="diffchange diffchange-inline">He confirmed drinking 750 ml energy drink without any further consumption of food and using an e-cigarette from Gaziantep, Turkey 10 seconds before </ins>the <ins class="diffchange diffchange-inline">onset of his </ins>first <ins class="diffchange diffchange-inline">symptoms. He usually smokes a pack of cigarettes a day </ins>and <ins class="diffchange diffchange-inline">sometimes smokes e-cigarettes</ins>. <ins class="diffchange diffchange-inline">Combined with non</ins>-<ins class="diffchange diffchange-inline">specific, transient symptoms, clinical recognition of SCRA intoxication is challenging </ins>.&lt;br&gt;<ins class="diffchange diffchange-inline">Data availability </ins>&lt;br&gt;<ins class="diffchange diffchange-inline">The intensity </ins>is <ins class="diffchange diffchange-inline">plotted against the retention time for both chromatograms, demonstrating the visit Cannabinoidsrc 4f Adb`s official website presence and elution profiles </ins>of <ins class="diffchange diffchange-inline">nicotine and ADB-BUTINACA in </ins>the <ins class="diffchange diffchange-inline">analysed vape liquid sample. LC-QTOF</ins>-<ins class="diffchange diffchange-inline">MS Chromatograms of Nicotine </ins>(<ins class="diffchange diffchange-inline">Top</ins>) and <ins class="diffchange diffchange-inline">ADB</ins>-<ins class="diffchange diffchange-inline">BUTINACA </ins>(<ins class="diffchange diffchange-inline">Bottom</ins>) <ins class="diffchange diffchange-inline">in </ins>the <ins class="diffchange diffchange-inline">Vape Liquid used by </ins>the <ins class="diffchange diffchange-inline">patient. The LC</ins>-<ins class="diffchange diffchange-inline">QTOF</ins>-<ins class="diffchange diffchange-inline">MS analysis showed that the e</ins>-<ins class="diffchange diffchange-inline">liquid contained nicotine and </ins>ADB-<ins class="diffchange diffchange-inline">BUTINACA </ins>(<ins class="diffchange diffchange-inline">Fig</ins>. <ins class="diffchange diffchange-inline">1)</ins>. <ins class="diffchange diffchange-inline">Because the point</ins>-<ins class="diffchange diffchange-inline">of</ins>-<ins class="diffchange diffchange-inline">care DOA test is generally </ins>not <ins class="diffchange diffchange-inline">able to detect synthetic recreational </ins>drug <ins class="diffchange diffchange-inline">substances</ins>, the <ins class="diffchange diffchange-inline">liquid of the e-cigarette </ins>was <ins class="diffchange diffchange-inline">thereafter screened using liquid chromatography-quadrupole time-of-flight mass spectrometry (LC-QTOF-MS) on the Waters™ Xevo G3 QTOF MS system</ins>. <ins class="diffchange diffchange-inline">After eating a light meal and drinking caffeinated sports drinks at the ER</ins>, the <ins class="diffchange diffchange-inline">nausea complaints of the patient were reduced and </ins>the <ins class="diffchange diffchange-inline">patient was discharged hom</ins>&lt;br&gt;&lt;br&gt;&lt;br&gt;<ins class="diffchange diffchange-inline">A limitation of this case report is that we did not have a urine sample available for additional NPS testing. Point</ins>-<ins class="diffchange diffchange-inline">of</ins>-<ins class="diffchange diffchange-inline">care DOA tests using urine to screen for misuse of multiple substances, regularly include cannabis, amphetamines</ins>, <ins class="diffchange diffchange-inline">cocaine</ins>, <ins class="diffchange diffchange-inline">opioids</ins>, <ins class="diffchange diffchange-inline">benzodiazepines </ins>and <ins class="diffchange diffchange-inline">methadone</ins>. <ins class="diffchange diffchange-inline">THC, methamphetamine</ins>, <ins class="diffchange diffchange-inline">SRCA, lysergic acid diethylamide (LSD</ins>), <ins class="diffchange diffchange-inline">gamma</ins>-<ins class="diffchange diffchange-inline">hydroxybutyrate </ins>(<ins class="diffchange diffchange-inline">GHB</ins>) and <ins class="diffchange diffchange-inline">ketamine are likely to become volatile under the temperature of current e</ins>-<ins class="diffchange diffchange-inline">cigarettes</ins>, <ins class="diffchange diffchange-inline">while crack cocaine is hard to vaporise. A systematic review including data of 114 patients of which the majority was intoxicated due to SCRA smoking revealed that 45 % of the patients who present at the ER after an intoxication due </ins>to <ins class="diffchange diffchange-inline">SCRA smoking recovered within 24 hours</ins>&lt;br&gt;&lt;br&gt;&lt;br&gt;<ins class="diffchange diffchange-inline">In </ins>the <ins class="diffchange diffchange-inline">present study, we performed various methods based on animal behavioral testing including FOB test for general behavioral observation, rotarod test, locomotor activity test for motor function evaluation, </ins>and <ins class="diffchange diffchange-inline">water</ins>-<ins class="diffchange diffchange-inline">maze test </ins>for <ins class="diffchange diffchange-inline">learning/memory evaluation</ins>. <ins class="diffchange diffchange-inline">Known for its stability </ins>and <ins class="diffchange diffchange-inline">consistent composition, this compound is frequently utilized by professionals seeking reliable materials </ins>for <ins class="diffchange diffchange-inline">laboratory-based analytical studies. In this study</ins>, <ins class="diffchange diffchange-inline">histopathological evaluation was performed to confirm the possibility of neurotoxicity </ins>of <ins class="diffchange diffchange-inline">the tested substances by hematoxylin and eosin staining method from collected brain samples</ins>. <ins class="diffchange diffchange-inline">In </ins>the <ins class="diffchange diffchange-inline">present study</ins>, <ins class="diffchange diffchange-inline">we evaluated </ins>the <ins class="diffchange diffchange-inline">neurotoxicity </ins>of <ins class="diffchange diffchange-inline">two synthetic cannabinoids (JWH-081 and JWH-210) </ins>through <ins class="diffchange diffchange-inline">observation of various behavioral changes </ins>and <ins class="diffchange diffchange-inline">analysis of histopathological changes using experimental mice with various doses (0.1, 1, 5 mg</ins>/<ins class="diffchange diffchange-inline">kg)</ins>. <ins class="diffchange diffchange-inline">Selecting powder JWH</ins>-<ins class="diffchange diffchange-inline">210 demands careful evaluation of purity, legality</ins>, <ins class="diffchange diffchange-inline">and supplier credibility</ins>. <ins class="diffchange diffchange-inline">Prices </ins>for <ins class="diffchange diffchange-inline">research-grade JWH-210 vary significantly based on quantity</ins>, <ins class="diffchange diffchange-inline">purity</ins>, and <ins class="diffchange diffchange-inline">vendor complianc</ins></div></td></tr> <!-- diff cache key stadtwiki:diff::1.12:old-34911:rev-34922 --> </table>

ScarlettCagle66 https://www.stadtwiki-strausberg.de/index.php?title=5F-ADB_Wikipedia&diff=34911&oldid=prev 2026-06-21T18:25:47Z

<p></p> <table class="diff diff-contentalign-left" data-mw="interface"> <col class="diff-marker" /> <col class="diff-content" /> <col class="diff-marker" /> <col class="diff-content" /> <tr class="diff-title" lang="de"> <td colspan="2" style="background-color: #fff; color: #222; text-align: center;">← Nächstältere Version</td> <td colspan="2" style="background-color: #fff; color: #222; text-align: center;">Version vom 21. Juni 2026, 18:25 Uhr</td> </tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l1" >Zeile 1:</td> <td colspan="2" class="diff-lineno">Zeile 1:</td></tr> <tr><td class='diff-marker'>−</td><td style="color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>4. Drugs &lt;br&gt;In general, the locomotor depressant and discriminative stimulus effects have been observed at doses that do not produce adverse effects, although tremors were observed upon handling in mice that received JWH-210 (Gatch et al., 2016), and 5F-AMB produced sustained vocalization and convulsions in rats (Gatch et al., 2018). All of the synthetic cannabinoids tested in the present study fully substituted for the discriminative stimulus effects of Δ9-THC. Subsequently, a one-way analysis of variance was conducted on horizontal activity counts for the 30-min period of maximal effect, and planned comparisons were conducted for each dose against the vehicle control using single degree-of-freedom F tests. A two-way analysis of variance, with dose as a between groups factor and time as a within subject factor, was conducted on horizontal activity counts/10 min interval. Locomotor activity in mice was tested to screen for locomotor depressant effects and to identify behaviorally-active dose ranges and times of peak effect. Previous studies have demonstrated that these compounds have chemical structures similar to synthetic cannabinoids known to have substantial abuse liability and act at the CB1 receptor.&lt;br&gt;Michael B Gatch &lt;br&gt;Substantial depressant effects were observed within the first 10 min, and maximal depression was observed between 0–30 min following administration. Tremors were observed 30 minutes following 1 mg/kg AMB-FUBINACA in 3 of 8 mice (data not shown). Substantial depressant effects were observed within the first 10 min, and maximal depression was observed between 10–40 min and lasted up to 2.5 to 3 h at the <del class="diffchange diffchange-inline">[https://cannabinoidsrc4f-adb.com/ </del>https://cannabinoidsrc4f-adb.com/<del class="diffchange diffchange-inline">] </del>highest dose tested (0.5 mg/kg).&lt;br&gt;Figure 1. &lt;br&gt;There is indication that at least some of the first-generation synthetic cannabinoids act at receptors other than cannabinoid CB1 and CB2 (Wiley et al., 2016), and a compound from the present study, 5F-MDMB-PINACA, was found to activate midbrain dopamine neurons, but not serotonin neurons (Asaoka et al., 2016). As previously mentioned, all of the compounds tested in the present study (MDMB-PINACA, MDMB-CHMICA, MDMB-FUBINACA, ADB-FUBINACA, and AMB-FUBINACA) act as agonists at CB1 receptors (Banister et al., 2015, 2016; Gamage et al., 2018), which suggests these compounds will produce Δ9-THC-like effects, including abuse liability. Tremors were not observed following AMB-FUBINACA during the drug discrimination study, but the maximum dose tested was only 0.1 mg/kg, which is 10-fold lower than the dose that produced tremors in the mice.&lt;br&gt;Michael B Gat<del class="diffchange diffchange-inline">&lt;br&gt;&lt;br&gt;&lt;br&gt;The same procedure was then applied to the mice once every day for 5 days. It was considered as coordination disturbance when mice fell from the test apparatus within 2 min. Mice that remained their position on the running apparatus at 10 rpm for at least 2 min were selected for further evaluation.&lt;br&gt;Table of Conten&lt;br&gt;&lt;br&gt;AMB-FUBINACA has been implicated in severe adverse effects in recreational users (Adams et al., 2017; Hamilton et al., 2017), which suggests that the range between behaviorally active and toxic doses of AMB-FUBINACA is narro&lt;br&gt;&lt;br&gt;&lt;br&gt;JWH-210 Chemical Powder offers a reliable solution for laboratories seeking a compound that meets stringent requirements. Researchers often require compounds that are consistent and dependable, and this product delivers on both fronts. Whether used in small-scale experiments or larger research projects, the compound maintains its integrity under recommended storage conditions. This ensures ease of handling and precise measurement during laboratory use. Each batch undergoes detailed verification to ensure purity, consistency, and accuracy, making it suitable for controlled experimental environments. This study was supported by a grant (13181MFDS654) of the National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety, Republic of Kore&lt;br&gt;&lt;br&gt;&lt;br&gt;When clinical presentation and/or initial DOA testing results are inconclusive, additional testing with LC-QTOF-MS can be valuable and is recommended. SCRAs and other NPS may not be detected by point-of-care DOA tests. In this case, the point-of-care DOA urine screening was not able to detect the synthetic cannabinoid ADB-BUTINAC&lt;br&gt;&lt;br&gt;Synthetic cannabinoids have consistently been shown to produce discriminative stimulus effects similar to those of Δ9-THC (Bannister and Connor, 2018), and MDMB-FUBINACA fully substituted for Δ9-THC (Gamage et al., 2018&lt;br&gt;&lt;br&gt;55 % of the patients required a longer admission due to symptoms such as severe tachycardia, hypertensive crise, convulsions, acute kidney insufficiency but also long-lasting, severe psychological problems</del>&lt;br&gt;&lt;br&gt;&lt;br&gt;These synthetic cannabinoids act directly at cannabinoid CB1 and CB2 receptors as does Δ9-tetrahydrocannabinol (Δ9-THC) found in marijuana, but have different chemical structures unrelated to Δ9-THC, different metabolism, and often greater toxicity (Fantegrossi et al., 2014). Discriminative stimulus effects were tested in rats trained to discriminate Δ9-tetrahydrocannabinol (3 mg/kg, 30-min pretreatment). 5F-MDMB-PINACA (also known as 5F-ADB, 5F-ADB-PINACA), MDMB-CHIMICA, MDMB-FUBINACA, ADB-FUBINACA, and AMB-FUBINACA (also known as FUB-AMB, MMB-FUBINACA) were tested for in vivo cannabinoid-like effects to assess their abuse liabilit</div></td><td class='diff-marker'>+</td><td style="color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins class="diffchange diffchange-inline">Tremors were not observed following AMB-FUBINACA during the drug discrimination study, but the maximum dose tested was only 0.1 mg/kg, which is 10-fold lower than the dose that produced tremors in the mic&lt;br&gt;&lt;br&gt;&lt;br&gt;A 30-min period, beginning when maximal depression of locomotor activity first appeared as a function of dose, was used for analysis of dose-response data and calculation of ED50 values. During test sessions, both levers were active, such that ten consecutive responses on either lever led to [https://cannabinoidsrc4f-adb.com/ https://cannabinoidsrc4f-adb.com/] reinforcement. The substitution tests occurred only if the rats had achieved 85% injection-appropriate responding on the two prior training sessions.&lt;br&gt;The locomotor activity assay was used to identify approximate time courses and dose ranges of psychoactive effects, which is useful for identifying parameters for drug discrimination experiments and are also predictive of the time course of the psychoactive effects in human users. The purpose of the present study was to assess the abuse liability of 5F-MDMB-PINACA, MDMB-CHIMICA, MDMB-FUBINACA, ADB-FUBINACA, and AMB-FUBINACA. Since there is currently no robust measure of the reinforcing/rewarding effects of cannabinoids, drug discrimination is currently the best model for assessing abuse liability of cannabinoids. The findings produce an apparent paradox, since CPP and self-administration predict with high reliability the likelihood that a compound will be abused by humans, and cannabinoids are well-known to produce active drug-seeking in human&lt;br&gt;&lt;br&gt;</ins>4. Drugs &lt;br&gt;In general, the locomotor depressant and discriminative stimulus effects have been observed at doses that do not produce adverse effects, although tremors were observed upon handling in mice that received JWH-210 (Gatch et al., 2016), and 5F-AMB produced sustained vocalization and convulsions in rats (Gatch et al., 2018). All of the synthetic cannabinoids tested in the present study fully substituted for the discriminative stimulus effects of Δ9-THC. Subsequently, a one-way analysis of variance was conducted on horizontal activity counts for the 30-min period of maximal effect, and planned comparisons were conducted for each dose against the vehicle control using single degree-of-freedom F tests. A two-way analysis of variance, with dose as a between groups factor and time as a within subject factor, was conducted on horizontal activity counts/10 min interval. Locomotor activity in mice was tested to screen for locomotor depressant effects and to identify behaviorally-active dose ranges and times of peak effect. Previous studies have demonstrated that these compounds have chemical structures similar to synthetic cannabinoids known to have substantial abuse liability and act at the CB1 receptor.&lt;br&gt;Michael B Gatch &lt;br&gt;Substantial depressant effects were observed within the first 10 min, and maximal depression was observed between 0–30 min following administration. Tremors were observed 30 minutes following 1 mg/kg AMB-FUBINACA in 3 of 8 mice (data not shown). Substantial depressant effects were observed within the first 10 min, and maximal depression was observed between 10–40 min and lasted up to 2.5 to 3 h at the https://cannabinoidsrc4f-adb.com/ highest dose tested (0.5 mg/kg).&lt;br&gt;Figure 1. &lt;br&gt;There is indication that at least some of the first-generation synthetic cannabinoids act at receptors other than cannabinoid CB1 and CB2 (Wiley et al., 2016), and a compound from the present study, 5F-MDMB-PINACA, was found to activate midbrain dopamine neurons, but not serotonin neurons (Asaoka et al., 2016). As previously mentioned, all of the compounds tested in the present study (MDMB-PINACA, MDMB-CHMICA, MDMB-FUBINACA, ADB-FUBINACA, and AMB-FUBINACA) act as agonists at CB1 receptors (Banister et al., 2015, 2016; Gamage et al., 2018), which suggests these compounds will produce Δ9-THC-like effects, including abuse liability. Tremors were not observed following AMB-FUBINACA during the drug discrimination study, but the maximum dose tested was only 0.1 mg/kg, which is 10-fold lower than the dose that produced tremors in the mice.&lt;br&gt;Michael B Gat&lt;br&gt;&lt;br&gt;&lt;br&gt;These synthetic cannabinoids act directly at cannabinoid CB1 and CB2 receptors as does Δ9-tetrahydrocannabinol (Δ9-THC) found in marijuana, but have different chemical structures unrelated to Δ9-THC, different metabolism, and often greater toxicity (Fantegrossi et al., 2014). Discriminative stimulus effects were tested in rats trained to discriminate Δ9-tetrahydrocannabinol (3 mg/kg, 30-min pretreatment). 5F-MDMB-PINACA (also known as 5F-ADB, 5F-ADB-PINACA), MDMB-CHIMICA, MDMB-FUBINACA, ADB-FUBINACA, and AMB-FUBINACA (also known as FUB-AMB, MMB-FUBINACA) were tested for in vivo cannabinoid-like effects to assess their abuse liabilit<ins class="diffchange diffchange-inline">&lt;br&gt;&lt;br&gt;&lt;br&gt;LC separates the urine or blood sample and QTOF-MS provides high-resolution and accurate mass measurements for precise identification and structural elucidation of compounds. The LC-QTOF-MS method offers a more comprehensive and sensitive approach for drug detection, covering hundreds of recreational drugs, including NPS. Besides increasing the temperature to enlarge the drug aerolisation and bioavailability, one can elevate the flow rate of air through the e-cigarette and/or add a diluent . Of all e-cigarette users registered at this forum, 7.8 % vaped SCRAs . About 15 % of individuals registered at forums for drug users such as erowid.org who vaped cannabis have also vaped SRCAs. SCRAs belong, together with synthetic opioids, cathinones, amphetamines and hallucinogens to the new psychoactive substances (NPS) that are currently developed at high speed.&lt;br&gt;Data availabili</ins></div></td></tr> <!-- diff cache key stadtwiki:diff::1.12:old-34897:rev-34911 --> </table>

AlizaMoberg10 https://www.stadtwiki-strausberg.de/index.php?title=5F-ADB_Wikipedia&diff=34897&oldid=prev 2026-06-21T18:13:26Z

<p></p> <table class="diff diff-contentalign-left" data-mw="interface"> <col class="diff-marker" /> <col class="diff-content" /> <col class="diff-marker" /> <col class="diff-content" /> <tr class="diff-title" lang="de"> <td colspan="2" style="background-color: #fff; color: #222; text-align: center;">← Nächstältere Version</td> <td colspan="2" style="background-color: #fff; color: #222; text-align: center;">Version vom 21. Juni 2026, 18:13 Uhr</td> </tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l1" >Zeile 1:</td> <td colspan="2" class="diff-lineno">Zeile 1:</td></tr> <tr><td class='diff-marker'>−</td><td style="color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del class="diffchange diffchange-inline">These synthetic cannabinoids act 4F ADB directly at cannabinoid CB1 and CB2 receptors as does Δ9-tetrahydrocannabinol (Δ9-THC) found in marijuana, but have different chemical structures unrelated to Δ9-THC, different metabolism, and often greater toxicity (Fantegrossi et al., 2014). Discriminative stimulus effects were tested in rats trained to discriminate Δ9-tetrahydrocannabinol (3 mg/kg, 30-min pretreatment). 5F-MDMB-PINACA (also known as 5F-ADB, 5F-ADB-PINACA), MDMB-CHIMICA, MDMB-FUBINACA, ADB-FUBINACA, and AMB-FUBINACA (also known as FUB-AMB, MMB-FUBINACA) were tested for in vivo cannabinoid-like effects to assess their abuse liabilit&lt;br&gt;&lt;br&gt;&lt;br&gt;LC-QTOF-MS represents a significant advancement in the field of drug detection, offering higher sensitivity, specificity, and a broader spectrum of detectable substances. Despite all negative results in the point-of-care test for recreational drugs, the liquid chromatography-quadrupole time-of-flight mass spectrometry (LC-QTOF-MS) analysis showed that the liquid of the e-cigarette contained ADB-BUTINACA, a synthetic cannabinoid. We report a 27-year-old man who was admitted to the emergency room because of sudden [https://cannabinoidsrc4f-adb.com/ 4F ADB] headache, nausea, vertigo, red eyes and palpitations. Synthetic cannabinoids are gaining popularity globally and detection is not commonly available.&lt;br&gt;Data availability &lt;br&gt;When clinical presentation and/or initial DOA testing results are inconclusive, additional testing with LC-QTOF-MS can be valuable and is recommended. SCRAs and other NPS may not be detected by point-of-care DOA tests. In this case, the point-of-care DOA urine screening was not able to detect the synthetic cannabinoid ADB-BUTINAC&lt;br&gt;&lt;br&gt;&lt;br&gt;Our findings revealed that both victims consumed large amounts of alcohol preceding their deaths (blood alcohol concentrations (BAC) were 2.11 and 2.49 g/L, respectively). Forensic autopsy of both victims was performed four days after the time of death following the Recommendation No.R (99)3 of the Council of Europe on medico-legal autopsies. Elegans demonstrated the ability to form all of the in-vivo metabolites and has the potential to be used as a complementary model to predict and characterize human metabolites, as well as identifying possible drug toxicities for emerging SCBs. Thus, identification of the relevant urinary markers was based primarily upon the prevalence of the in-vivo metabolites instead of the metabolites ranking that was based upon % peak area abundance ratio. Moreover, genetic makeup, physiological conditions (age, gender 4F ADB and ethnicity), environmental influences (diet) and pathological factors (liver diseases, diabetes, and obesity) would further complicate the metabolism of drugs. It should be noted that % peak area abundance ratios do not necessarily reflect absolute concentrations due to differences in ionization capacity and matrix effects bias for each metabolite.&lt;br&gt;Data concerning the combined effects of SCRAs and other substances are highly limited, which renders forensic evaluation of possible overdose cases difficult . The threshold SCRA concentration for fatal overdose can be estimated ng/mL level (0.37–4.1 ng/mL according to the reported cases) in cases in which 1.5–2.5 g/L of ethanol is present in the blood. The victims were brothers who were both found deceased after consuming 4F-MDMB-BINACA and ethanol. These confusing shorter names were not scientifically adopted but were used by websites selling the drugs to the public. Monitoring metabolism of synthetic cannabinoid 4F-MDMB-BINACA via high-resolution mass spectrometry assessed in cultured hepatoma cell line, fungus, liver microsomes and confirmed using urine samples. This article does not contain any studies with human participants or animals performed by any of the author&lt;br&gt;&lt;br&gt;&lt;br&gt;Test 2 was performed everyday for 5 days after consecutive administration of the substances, including negative (vehicle) and positive (methamphetamine) controls. After the last administration, the first trial was performed. Morris water maze test was performed to evaluate the changes of learning and memory function through administration of the test substances. Generally, neurotoxicity of a substance is evaluated by animal behavioral aspects, i.e. functional observation battery (FOB) tests (O’Callaghan et al., 2014). Our results suggest that JWH-081 and JWH-210 may 4F ADB be neurotoxic substances through changing neuronal cell damages, especially in the core shell part of nucleus accumbens.&lt;br&gt;About Powder JWH-2&lt;br&gt;&lt;br&gt;Moreover, genetic makeup, physiological conditions (age, gender and ethnicity), environmental influences (diet) and pathological factors (liver diseases, diabetes, and obesity) would further complicate the metabolism of drug&lt;br&gt;&lt;br&gt;</del>4. Drugs &lt;br&gt;In general, the locomotor depressant and discriminative stimulus effects have been observed at doses that do not produce adverse effects, although tremors were observed upon handling in mice that received JWH-210 (Gatch et al., 2016), and 5F-AMB produced sustained vocalization and convulsions in rats (Gatch et al., 2018). All of the synthetic cannabinoids tested in the present study fully substituted for the discriminative stimulus effects of Δ9-THC. Subsequently, a one-way analysis of variance was conducted on horizontal activity counts for the 30-min period of maximal effect, and planned comparisons were conducted for each dose against the vehicle control using single degree-of-freedom F tests. A two-way analysis of variance, with dose as a between groups factor and time as a within subject factor, was conducted on horizontal activity counts/10 min interval. Locomotor activity in mice was tested to screen for locomotor depressant effects and to identify behaviorally-active dose ranges and times of peak effect. Previous studies have demonstrated that these compounds have chemical structures similar to synthetic cannabinoids known to have substantial abuse liability and act at the CB1 receptor.&lt;br&gt;Michael B Gatch &lt;br&gt;Substantial depressant effects were observed within the first 10 min, and maximal depression was observed between 0–30 min following administration. Tremors were observed 30 minutes following 1 mg/kg AMB-FUBINACA in 3 of 8 mice (data not shown). Substantial depressant effects were observed within the first 10 min, and maximal depression was observed between 10–40 min and lasted up to 2.5 to 3 h at the <del class="diffchange diffchange-inline">4F ADB </del>highest dose tested (0.5 mg/kg).&lt;br&gt;Figure 1. &lt;br&gt;There is indication that at least some of the first-generation synthetic cannabinoids act at receptors other than cannabinoid CB1 and CB2 (Wiley et al., 2016), and a compound from the present study, 5F-MDMB-PINACA, was found to activate midbrain dopamine neurons, but not serotonin neurons (Asaoka et al., 2016). As previously mentioned, all of the compounds tested in the present study (MDMB-PINACA, MDMB-CHMICA, MDMB-FUBINACA, ADB-FUBINACA, and AMB-FUBINACA) act as agonists at CB1 receptors (Banister et al., 2015, 2016; Gamage et al., 2018), which suggests these compounds will produce Δ9-THC-like effects, including abuse liability. Tremors were not observed following AMB-FUBINACA during the drug discrimination study, but the maximum dose tested was only 0.1 mg/kg, which is 10-fold lower than the dose that produced tremors in the <del class="diffchange diffchange-inline">mic</del></div></td><td class='diff-marker'>+</td><td style="color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>4. Drugs &lt;br&gt;In general, the locomotor depressant and discriminative stimulus effects have been observed at doses that do not produce adverse effects, although tremors were observed upon handling in mice that received JWH-210 (Gatch et al., 2016), and 5F-AMB produced sustained vocalization and convulsions in rats (Gatch et al., 2018). All of the synthetic cannabinoids tested in the present study fully substituted for the discriminative stimulus effects of Δ9-THC. Subsequently, a one-way analysis of variance was conducted on horizontal activity counts for the 30-min period of maximal effect, and planned comparisons were conducted for each dose against the vehicle control using single degree-of-freedom F tests. A two-way analysis of variance, with dose as a between groups factor and time as a within subject factor, was conducted on horizontal activity counts/10 min interval. Locomotor activity in mice was tested to screen for locomotor depressant effects and to identify behaviorally-active dose ranges and times of peak effect. Previous studies have demonstrated that these compounds have chemical structures similar to synthetic cannabinoids known to have substantial abuse liability and act at the CB1 receptor.&lt;br&gt;Michael B Gatch &lt;br&gt;Substantial depressant effects were observed within the first 10 min, and maximal depression was observed between 0–30 min following administration. Tremors were observed 30 minutes following 1 mg/kg AMB-FUBINACA in 3 of 8 mice (data not shown). Substantial depressant effects were observed within the first 10 min, and maximal depression was observed between 10–40 min and lasted up to 2.5 to 3 h at the <ins class="diffchange diffchange-inline">[https://cannabinoidsrc4f-adb.com/ https://cannabinoidsrc4f-adb.com/] </ins>highest dose tested (0.5 mg/kg).&lt;br&gt;Figure 1. &lt;br&gt;There is indication that at least some of the first-generation synthetic cannabinoids act at receptors other than cannabinoid CB1 and CB2 (Wiley et al., 2016), and a compound from the present study, 5F-MDMB-PINACA, was found to activate midbrain dopamine neurons, but not serotonin neurons (Asaoka et al., 2016). As previously mentioned, all of the compounds tested in the present study (MDMB-PINACA, MDMB-CHMICA, MDMB-FUBINACA, ADB-FUBINACA, and AMB-FUBINACA) act as agonists at CB1 receptors (Banister et al., 2015, 2016; Gamage et al., 2018), which suggests these compounds will produce Δ9-THC-like effects, including abuse liability. Tremors were not observed following AMB-FUBINACA during the drug discrimination study, but the maximum dose tested was only 0.1 mg/kg, which is 10-fold lower than the dose that produced tremors in the <ins class="diffchange diffchange-inline">mice.&lt;br&gt;Michael B Gat&lt;br&gt;&lt;br&gt;&lt;br&gt;The same procedure was then applied to the mice once every day for 5 days. It was considered as coordination disturbance when mice fell from the test apparatus within 2 min. Mice that remained their position on the running apparatus at 10 rpm for at least 2 min were selected for further evaluation.&lt;br&gt;Table of Conten&lt;br&gt;&lt;br&gt;AMB-FUBINACA has been implicated in severe adverse effects in recreational users (Adams et al., 2017; Hamilton et al., 2017), which suggests that the range between behaviorally active and toxic doses of AMB-FUBINACA is narro&lt;br&gt;&lt;br&gt;&lt;br&gt;JWH-210 Chemical Powder offers a reliable solution for laboratories seeking a compound that meets stringent requirements. Researchers often require compounds that are consistent and dependable, and this product delivers on both fronts. Whether used in small-scale experiments or larger research projects, the compound maintains its integrity under recommended storage conditions. This ensures ease of handling and precise measurement during laboratory use. Each batch undergoes detailed verification to ensure purity, consistency, and accuracy, making it suitable for controlled experimental environments. This study was supported by a grant (13181MFDS654) of the National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety, Republic of Kore&lt;br&gt;&lt;br&gt;&lt;br&gt;When clinical presentation and/or initial DOA testing results are inconclusive, additional testing with LC-QTOF-MS can be valuable and is recommended. SCRAs and other NPS may not be detected by point-of-care DOA tests. In this case, the point-of-care DOA urine screening was not able to detect the synthetic cannabinoid ADB-BUTINAC&lt;br&gt;&lt;br&gt;Synthetic cannabinoids have consistently been shown to produce discriminative stimulus effects similar to those of Δ9-THC (Bannister and Connor, 2018), and MDMB-FUBINACA fully substituted for Δ9-THC (Gamage et al., 2018&lt;br&gt;&lt;br&gt;55 % of the patients required a longer admission due to symptoms such as severe tachycardia, hypertensive crise, convulsions, acute kidney insufficiency but also long-lasting, severe psychological problems&lt;br&gt;&lt;br&gt;&lt;br&gt;These synthetic cannabinoids act directly at cannabinoid CB1 and CB2 receptors as does Δ9-tetrahydrocannabinol (Δ9-THC) found in marijuana, but have different chemical structures unrelated to Δ9-THC, different metabolism, and often greater toxicity (Fantegrossi et al., 2014). Discriminative stimulus effects were tested in rats trained to discriminate Δ9-tetrahydrocannabinol (3 mg/kg, 30-min pretreatment). 5F-MDMB-PINACA (also known as 5F-ADB, 5F-ADB-PINACA), MDMB-CHIMICA, MDMB-FUBINACA, ADB-FUBINACA, and AMB-FUBINACA (also known as FUB-AMB, MMB-FUBINACA) were tested for in vivo cannabinoid-like effects to assess their abuse liabilit</ins></div></td></tr> <!-- diff cache key stadtwiki:diff::1.12:old-28610:rev-34897 --> </table>

AlizaMoberg10 https://www.stadtwiki-strausberg.de/index.php?title=5F-ADB_Wikipedia&diff=28610&oldid=prev 2026-06-04T08:48:06Z

<p></p> <table class="diff diff-contentalign-left" data-mw="interface"> <col class="diff-marker" /> <col class="diff-content" /> <col class="diff-marker" /> <col class="diff-content" /> <tr class="diff-title" lang="de"> <td colspan="2" style="background-color: #fff; color: #222; text-align: center;">← Nächstältere Version</td> <td colspan="2" style="background-color: #fff; color: #222; text-align: center;">Version vom 4. Juni 2026, 08:48 Uhr</td> </tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l1" >Zeile 1:</td> <td colspan="2" class="diff-lineno">Zeile 1:</td></tr> <tr><td class='diff-marker'>−</td><td style="color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del class="diffchange diffchange-inline">After the incubation, mixture was centrifuged </del>(<del class="diffchange diffchange-inline">18</del>,<del class="diffchange diffchange-inline">000 x g</del>, <del class="diffchange diffchange-inline">20 °C) for 5 min and 0.5 μL of the supernatant was directly injected to the chromatographic system. In the next step</del>, <del class="diffchange diffchange-inline">ammonium formate as salting agent was added to the mixture </del>and <del class="diffchange diffchange-inline">incubated in a thermomixer </del>(<del class="diffchange diffchange-inline">20 °C</del>, <del class="diffchange diffchange-inline">1200 rpm</del>) <del class="diffchange diffchange-inline">for 15 min</del>. <del class="diffchange diffchange-inline">After vortex</del>-<del class="diffchange diffchange-inline">mixing</del>, <del class="diffchange diffchange-inline">the mixture was allowed to stand 5CLADBA at room temperature for 5 </del>min<del class="diffchange diffchange-inline">. MS/MS experiments were performed in MRM (multiple reaction monitoring</del>) <del class="diffchange diffchange-inline">mode with an isolation window of 0</del>.<del class="diffchange diffchange-inline">4 m/z. The MS measurement was performed in positive ion mode </del>(<del class="diffchange diffchange-inline">except for some acidic compounds such </del>as <del class="diffchange diffchange-inline">barbiturates&lt;br&gt;&lt;br&gt;The % peak area abundance ratio of metabolites detected in the urine samples are often affected by numerous factors such as drug intake behaviour (intake route</del>, <del class="diffchange diffchange-inline">amount of drug and intake frequency</del>), <del class="diffchange diffchange-inline">time from last drug intake </del>and <del class="diffchange diffchange-inline">metabolic stabilit</del>&lt;br&gt;&lt;br&gt;&lt;br&gt;LC-QTOF-MS represents a significant advancement in the field of drug detection, offering higher sensitivity, specificity, and a broader spectrum of detectable substances. Despite all negative results in the point-of-care test for recreational drugs, the liquid chromatography-quadrupole time-of-flight mass spectrometry (LC-QTOF-MS) analysis showed that the liquid of the e-cigarette contained ADB-BUTINACA, a synthetic cannabinoid. We report a 27-year-old man who was admitted to the emergency room because of sudden <del class="diffchange diffchange-inline">5CLADBA </del>headache, nausea, vertigo, red eyes and palpitations. Synthetic cannabinoids are gaining popularity globally and detection is not commonly available.&lt;br&gt;Data availability &lt;br&gt;When clinical presentation and/or initial DOA testing results are inconclusive, additional testing with LC-QTOF-MS can be valuable and is recommended. SCRAs and other NPS may not be detected by point-of-care DOA tests. In this case, the point-of-care DOA urine screening was not able to detect the synthetic cannabinoid ADB-BUTINAC&lt;br&gt;&lt;br&gt;4. Drugs &lt;br&gt;In general, the locomotor depressant and discriminative stimulus effects have been observed at doses that do not produce adverse effects, although tremors were observed upon handling in mice that received JWH-210 (Gatch et al., 2016), and 5F-AMB produced sustained vocalization and convulsions in rats (Gatch et al., 2018). All of the synthetic cannabinoids tested in the present study fully substituted for the discriminative stimulus effects of Δ9-THC. Subsequently, a one-way analysis of variance was conducted on horizontal activity counts for the 30-min period of maximal effect, and planned comparisons were conducted for each dose against the vehicle control using single degree-of-freedom F tests. A two-way analysis of variance, with dose as a between groups factor and time as a within subject factor, was conducted on horizontal activity counts/10 min interval. Locomotor activity in mice was tested to screen for locomotor depressant effects and to identify behaviorally-active dose ranges and times of peak effect. Previous studies have demonstrated that these compounds have chemical structures similar to synthetic cannabinoids known to have substantial abuse liability and act at the CB1 receptor.&lt;br&gt;Michael B Gatch &lt;br&gt;Substantial depressant effects were observed within the first 10 min, and maximal depression was observed between 0–30 min following administration. Tremors were observed 30 minutes following 1 mg/kg AMB-FUBINACA in 3 of 8 mice (data not shown). Substantial depressant effects were observed within the first 10 min, and maximal depression was observed between 10–40 min and lasted up to 2.5 to 3 h at the <del class="diffchange diffchange-inline">[https://cannabinoidsrc4f-adb.com/ 5CLADBA] </del>highest dose tested (0.5 mg/kg).&lt;br&gt;Figure 1. &lt;br&gt;There is indication that at least some of the first-generation synthetic cannabinoids act at receptors other than cannabinoid CB1 and CB2 (Wiley et al., 2016), and a compound from the present study, 5F-MDMB-PINACA, was found to activate midbrain dopamine neurons, but not serotonin neurons (Asaoka et al., 2016). As previously mentioned, all of the compounds tested in the present study (MDMB-PINACA, MDMB-CHMICA, MDMB-FUBINACA, ADB-FUBINACA, and AMB-FUBINACA) act as agonists at CB1 receptors (Banister et al., 2015, 2016; Gamage et al., 2018), which suggests these compounds will produce Δ9-THC-like effects, including abuse liability. Tremors were not observed following AMB-FUBINACA during the drug discrimination study, but the maximum dose tested was only 0.1 mg/kg, which is 10-fold lower than the dose that produced tremors in the mic<del class="diffchange diffchange-inline">&lt;br&gt;&lt;br&gt;Tremors were not observed following AMB-FUBINACA during the drug discrimination study, but the maximum dose tested was only 0.1 mg/kg, which is 10-fold lower than the dose that produced tremors in the mic&lt;br&gt;&lt;br&gt;&lt;br&gt;The same procedure was then applied to the mice once every day for 5 days. It was considered as coordination disturbance when mice fell from the test apparatus within 2 min. Mice that remained their position on the running apparatus at 10 rpm for at least 2 min were selected for further evaluation.&lt;br&gt;Table of Conten</del></div></td><td class='diff-marker'>+</td><td style="color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins class="diffchange diffchange-inline">These synthetic cannabinoids act 4F ADB directly at cannabinoid CB1 and CB2 receptors as does Δ9-tetrahydrocannabinol </ins>(<ins class="diffchange diffchange-inline">Δ9-THC) found in marijuana</ins>, <ins class="diffchange diffchange-inline">but have different chemical structures unrelated to Δ9-THC</ins>, <ins class="diffchange diffchange-inline">different metabolism</ins>, and <ins class="diffchange diffchange-inline">often greater toxicity </ins>(<ins class="diffchange diffchange-inline">Fantegrossi et al.</ins>, <ins class="diffchange diffchange-inline">2014</ins>). <ins class="diffchange diffchange-inline">Discriminative stimulus effects were tested in rats trained to discriminate Δ9</ins>-<ins class="diffchange diffchange-inline">tetrahydrocannabinol (3 mg/kg</ins>, <ins class="diffchange diffchange-inline">30-</ins>min <ins class="diffchange diffchange-inline">pretreatment</ins>). <ins class="diffchange diffchange-inline">5F-MDMB-PINACA </ins>(<ins class="diffchange diffchange-inline">also known </ins>as <ins class="diffchange diffchange-inline">5F-ADB</ins>, <ins class="diffchange diffchange-inline">5F-ADB-PINACA</ins>), <ins class="diffchange diffchange-inline">MDMB-CHIMICA, MDMB-FUBINACA, ADB-FUBINACA, </ins>and <ins class="diffchange diffchange-inline">AMB-FUBINACA (also known as FUB-AMB, MMB-FUBINACA) were tested for in vivo cannabinoid-like effects to assess their abuse liabilit</ins>&lt;br&gt;&lt;br&gt;&lt;br&gt;LC-QTOF-MS represents a significant advancement in the field of drug detection, offering higher sensitivity, specificity, and a broader spectrum of detectable substances. Despite all negative results in the point-of-care test for recreational drugs, the liquid chromatography-quadrupole time-of-flight mass spectrometry (LC-QTOF-MS) analysis showed that the liquid of the e-cigarette contained ADB-BUTINACA, a synthetic cannabinoid. We report a 27-year-old man who was admitted to the emergency room because of sudden <ins class="diffchange diffchange-inline">[https://cannabinoidsrc4f-adb.com/ 4F ADB] </ins>headache, nausea, vertigo, red eyes and palpitations. Synthetic cannabinoids are gaining popularity globally and detection is not commonly available.&lt;br&gt;Data availability &lt;br&gt;When clinical presentation and/or initial DOA testing results are inconclusive, additional testing with LC-QTOF-MS can be valuable and is recommended. SCRAs and other NPS may not be detected by point-of-care DOA tests. In this case, the point-of-care DOA urine screening was not able to detect the synthetic cannabinoid ADB-BUTINAC<ins class="diffchange diffchange-inline">&lt;br&gt;&lt;br&gt;&lt;br&gt;Our findings revealed that both victims consumed large amounts of alcohol preceding their deaths (blood alcohol concentrations (BAC) were 2.11 and 2.49 g/L, respectively). Forensic autopsy of both victims was performed four days after the time of death following the Recommendation No.R (99)3 of the Council of Europe on medico-legal autopsies. Elegans demonstrated the ability to form all of the in-vivo metabolites and has the potential to be used as a complementary model to predict and characterize human metabolites, as well as identifying possible drug toxicities for emerging SCBs. Thus, identification of the relevant urinary markers was based primarily upon the prevalence of the in-vivo metabolites instead of the metabolites ranking that was based upon % peak area abundance ratio. Moreover, genetic makeup, physiological conditions (age, gender 4F ADB and ethnicity), environmental influences (diet) and pathological factors (liver diseases, diabetes, and obesity) would further complicate the metabolism of drugs. It should be noted that % peak area abundance ratios do not necessarily reflect absolute concentrations due to differences in ionization capacity and matrix effects bias for each metabolite.&lt;br&gt;Data concerning the combined effects of SCRAs and other substances are highly limited, which renders forensic evaluation of possible overdose cases difficult . The threshold SCRA concentration for fatal overdose can be estimated ng/mL level (0.37–4.1 ng/mL according to the reported cases) in cases in which 1.5–2.5 g/L of ethanol is present in the blood. The victims were brothers who were both found deceased after consuming 4F-MDMB-BINACA and ethanol. These confusing shorter names were not scientifically adopted but were used by websites selling the drugs to the public. Monitoring metabolism of synthetic cannabinoid 4F-MDMB-BINACA via high-resolution mass spectrometry assessed in cultured hepatoma cell line, fungus, liver microsomes and confirmed using urine samples. This article does not contain any studies with human participants or animals performed by any of the author&lt;br&gt;&lt;br&gt;&lt;br&gt;Test 2 was performed everyday for 5 days after consecutive administration of the substances, including negative (vehicle) and positive (methamphetamine) controls. After the last administration, the first trial was performed. Morris water maze test was performed to evaluate the changes of learning and memory function through administration of the test substances. Generally, neurotoxicity of a substance is evaluated by animal behavioral aspects, i.e. functional observation battery (FOB) tests (O’Callaghan et al., 2014). Our results suggest that JWH-081 and JWH-210 may 4F ADB be neurotoxic substances through changing neuronal cell damages, especially in the core shell part of nucleus accumbens.&lt;br&gt;About Powder JWH-2&lt;br&gt;&lt;br&gt;Moreover, genetic makeup, physiological conditions (age, gender and ethnicity), environmental influences (diet) and pathological factors (liver diseases, diabetes, and obesity) would further complicate the metabolism of drug</ins>&lt;br&gt;&lt;br&gt;4. Drugs &lt;br&gt;In general, the locomotor depressant and discriminative stimulus effects have been observed at doses that do not produce adverse effects, although tremors were observed upon handling in mice that received JWH-210 (Gatch et al., 2016), and 5F-AMB produced sustained vocalization and convulsions in rats (Gatch et al., 2018). All of the synthetic cannabinoids tested in the present study fully substituted for the discriminative stimulus effects of Δ9-THC. Subsequently, a one-way analysis of variance was conducted on horizontal activity counts for the 30-min period of maximal effect, and planned comparisons were conducted for each dose against the vehicle control using single degree-of-freedom F tests. A two-way analysis of variance, with dose as a between groups factor and time as a within subject factor, was conducted on horizontal activity counts/10 min interval. Locomotor activity in mice was tested to screen for locomotor depressant effects and to identify behaviorally-active dose ranges and times of peak effect. Previous studies have demonstrated that these compounds have chemical structures similar to synthetic cannabinoids known to have substantial abuse liability and act at the CB1 receptor.&lt;br&gt;Michael B Gatch &lt;br&gt;Substantial depressant effects were observed within the first 10 min, and maximal depression was observed between 0–30 min following administration. Tremors were observed 30 minutes following 1 mg/kg AMB-FUBINACA in 3 of 8 mice (data not shown). Substantial depressant effects were observed within the first 10 min, and maximal depression was observed between 10–40 min and lasted up to 2.5 to 3 h at the <ins class="diffchange diffchange-inline">4F ADB </ins>highest dose tested (0.5 mg/kg).&lt;br&gt;Figure 1. &lt;br&gt;There is indication that at least some of the first-generation synthetic cannabinoids act at receptors other than cannabinoid CB1 and CB2 (Wiley et al., 2016), and a compound from the present study, 5F-MDMB-PINACA, was found to activate midbrain dopamine neurons, but not serotonin neurons (Asaoka et al., 2016). As previously mentioned, all of the compounds tested in the present study (MDMB-PINACA, MDMB-CHMICA, MDMB-FUBINACA, ADB-FUBINACA, and AMB-FUBINACA) act as agonists at CB1 receptors (Banister et al., 2015, 2016; Gamage et al., 2018), which suggests these compounds will produce Δ9-THC-like effects, including abuse liability. Tremors were not observed following AMB-FUBINACA during the drug discrimination study, but the maximum dose tested was only 0.1 mg/kg, which is 10-fold lower than the dose that produced tremors in the mic</div></td></tr> <!-- diff cache key stadtwiki:diff::1.12:old-28604:rev-28610 --> </table>

AlizaMoberg10 https://www.stadtwiki-strausberg.de/index.php?title=5F-ADB_Wikipedia&diff=28604&oldid=prev 2026-06-04T08:46:31Z

<p></p> <table class="diff diff-contentalign-left" data-mw="interface"> <col class="diff-marker" /> <col class="diff-content" /> <col class="diff-marker" /> <col class="diff-content" /> <tr class="diff-title" lang="de"> <td colspan="2" style="background-color: #fff; color: #222; text-align: center;">← Nächstältere Version</td> <td colspan="2" style="background-color: #fff; color: #222; text-align: center;">Version vom 4. Juni 2026, 08:46 Uhr</td> </tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l1" >Zeile 1:</td> <td colspan="2" class="diff-lineno">Zeile 1:</td></tr> <tr><td class='diff-marker'>−</td><td style="color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del class="diffchange diffchange-inline">LC separates the urine or blood sample and QTOF-MS provides high-resolution and accurate mass measurements for precise identification and structural elucidation of compounds. The LC-QTOF-MS method offers a more comprehensive and sensitive approach for drug detection, covering hundreds of recreational drugs, including NPS. Besides increasing the temperature to enlarge the drug aerolisation and bioavailability, one can elevate the flow rate of air through the e-cigarette and/or add a diluent . Of all e-cigarette users registered at this forum, 7.8 % vaped SCRAs . About 15 % of individuals registered at forums for drug users such as erowid.org who vaped cannabis have also vaped SRCAs. SCRAs belong, together with synthetic opioids, cathinones, amphetamines and hallucinogens to the new psychoactive substances (NPS) that are currently developed at high speed.&lt;br&gt;Data availabili&lt;br&gt;&lt;br&gt;&lt;br&gt;</del>After the incubation, mixture was centrifuged (18,000 x g, 20 °C) for 5 min and 0.5 μL of the supernatant was directly injected to the chromatographic system. In the next step, ammonium formate as salting agent was added to the mixture and incubated in a thermomixer (20 °C, 1200 rpm) for 15 min. After vortex-mixing, the mixture was allowed to stand <del class="diffchange diffchange-inline">Https://Cannabinoidsrc4F-Adb.Com/ </del>at room temperature for 5 min. MS/MS experiments were performed in MRM (multiple reaction monitoring) mode with an isolation window of 0.4 m/z. The MS measurement was performed in positive ion mode (except for some acidic compounds such as barbiturates&lt;br&gt;&lt;br&gt;<del class="diffchange diffchange-inline">&lt;br&gt;Product ions </del>detected <del class="diffchange diffchange-inline">at m/z 302, 217</del>, and <del class="diffchange diffchange-inline">145 (B2</del>) <del class="diffchange diffchange-inline">confirmed that tert-leucine </del>and <del class="diffchange diffchange-inline">indazole moieties remained unchanged, leading to the structure elucidation of a hydroxy</del>-<del class="diffchange diffchange-inline">functional group at the 4</del>-<del class="diffchange diffchange-inline">position of the butyl side chain by oxidative defluorination. The product ion m/z 336 (loss of methyl ester moiety) further confirmed </del>the <del class="diffchange diffchange-inline">presence </del>of <del class="diffchange diffchange-inline">dihydroxylated metabolites. The precursor ion</del>, <del class="diffchange diffchange-inline">m/z 364 (B14</del>, <del class="diffchange diffchange-inline">B5/B6) had </del>a <del class="diffchange diffchange-inline">loss </del>of <del class="diffchange diffchange-inline">2 Da from m/z 366 indicated further dehydrogenation of the ester hydrolysis plus monohydroxylated metabolites</del>. <del class="diffchange diffchange-inline">The presence of </del>the <del class="diffchange diffchange-inline">product ion m/z 320, likely formed from a loss </del>of <del class="diffchange diffchange-inline">carbon dioxide</del>, <del class="diffchange diffchange-inline">indicated monohydroxylation at </del>the <del class="diffchange diffchange-inline">tert</del>-<del class="diffchange diffchange-inline">leucine in B8 </del>(<del class="diffchange diffchange-inline">m/z 219</del>), <del class="diffchange diffchange-inline">butyl side chain in B9 (m/z 145) and indazole moiety in B13 (m/z 161)</del>. <del class="diffchange diffchange-inline">The precursor ion, m/z 350 showed </del>a <del class="diffchange diffchange-inline">loss of 14 Da explaining </del>the <del class="diffchange diffchange-inline">hydrolysis </del>of <del class="diffchange diffchange-inline">methyl ester from 4F-MDMB-BINACA</del>.&lt;br&gt;<del class="diffchange diffchange-inline">Fig. 2. </del>&lt;br&gt;<del class="diffchange diffchange-inline">The precursor ion m</del>/<del class="diffchange diffchange-inline">z 396 (B10</del>, <del class="diffchange diffchange-inline">B12/B15) was 32 Da higher than the parent drug, 4F</del>-<del class="diffchange diffchange-inline">MDMB</del>-<del class="diffchange diffchange-inline">BINACA</del>, <del class="diffchange diffchange-inline">suggesting </del>the <del class="diffchange diffchange-inline">addition </del>of <del class="diffchange diffchange-inline">two hydroxy groups</del>. <del class="diffchange diffchange-inline">All </del>the <del class="diffchange diffchange-inline">below explanations for transformations into metabolites are based on the data shown </del>in <del class="diffchange diffchange-inline">Fig</del>. <del class="diffchange diffchange-inline">Metabolites were identified according to their precursor ions</del>, <del class="diffchange diffchange-inline">product ions</del>, and <del class="diffchange diffchange-inline">fragmentation patterns </del>(<del class="diffchange diffchange-inline">Fig</del>. <del class="diffchange diffchange-inline">1</del>). <del class="diffchange diffchange-inline">Traditional </del>in-<del class="diffchange diffchange-inline">vivo metabolism studies to generate human metabolites </del>of <del class="diffchange diffchange-inline">drugs relied heavily </del>on the <del class="diffchange diffchange-inline">use </del>of <del class="diffchange diffchange-inline">whole animal model systems</del>, <del class="diffchange diffchange-inline">which are expensive, limited by drug administration amount, influenced by species variation </del>and <del class="diffchange diffchange-inline">faced by many ethical issues</del>. <del class="diffchange diffchange-inline">Eight in</del>-<del class="diffchange diffchange-inline">vivo metabolites tentatively identified were mainly products </del>of <del class="diffchange diffchange-inline">ester hydrolysis </del>with <del class="diffchange diffchange-inline">or without additional dehydrogenation</del>, <del class="diffchange diffchange-inline">N</del>-<del class="diffchange diffchange-inline">dealkylation, monohydroxylation </del>and <del class="diffchange diffchange-inline">oxidative defluorination with further oxidation </del>to <del class="diffchange diffchange-inline">butanoic acid</del>.&lt;br&gt;<del class="diffchange diffchange-inline">Fig. 1. </del>&lt;br&gt;<del class="diffchange diffchange-inline">This outcome </del>was <del class="diffchange diffchange-inline">anticipated since CES</del>-<del class="diffchange diffchange-inline">mediated hydrolysis is commonly </del>[https://cannabinoidsrc4f-adb.com/ <del class="diffchange diffchange-inline">Https:</del>/<del class="diffchange diffchange-inline">/Cannabinoidsrc4F-Adb</del>.<del class="diffchange diffchange-inline">Com/] reported as </del>the <del class="diffchange diffchange-inline">major metabolic pathway among the SCBs impacting the terminal ester group . Glucosides </del>and <del class="diffchange diffchange-inline">sulfate metabolites have been reported with other SCBs where C</del>. <del class="diffchange diffchange-inline">From these three samples</del>, <del class="diffchange diffchange-inline">sample 2 contained only an ester hydrolysis metabolite (m/z 350</del>)<del class="diffchange diffchange-inline">. Both ester hydrolysis followed by oxidative defluorination to butanoic acid (B4</del>, <del class="diffchange diffchange-inline">m/z 362) </del>and <del class="diffchange diffchange-inline">monohydroxylation at tert</del>-<del class="diffchange diffchange-inline">leucine moiety (B8</del>, <del class="diffchange diffchange-inline">m/z 366) metabolites were </del>found <del class="diffchange diffchange-inline">in 16/20 urine samples </del>(<del class="diffchange diffchange-inline">Table 2</del>). <del class="diffchange diffchange-inline">A In-vitro metabolites observed in common among respective seven most abundant metabolites in b C. The product ion detected at m/z 235</del>, <del class="diffchange diffchange-inline">indicating loss </del>of <del class="diffchange diffchange-inline">sulfate, confirmed </del>the <del class="diffchange diffchange-inline">identity of </del>the <del class="diffchange diffchange-inline">sulfation metabolite.&lt;br&gt;Fungus C. elegans &lt;br&gt;Methyl </del>(<del class="diffchange diffchange-inline">2S)</del>-<del class="diffchange diffchange-inline">2</del>-<del class="diffchange diffchange-inline">([1-(4-fluorobutyl)-1H-indazole-3-carbonyl]amino)-3</del>,<del class="diffchange diffchange-inline">3-dimethylbutanoate (4F-</del>MDMB-<del class="diffchange diffchange-inline">BINACA</del>, <del class="diffchange diffchange-inline">4F</del>-<del class="diffchange diffchange-inline">MDMB-BUTINACA or 4F</del>-<del class="diffchange diffchange-inline">ADB</del>), <del class="diffchange diffchange-inline">found in numerous SCB product seizures</del>, <del class="diffchange diffchange-inline">has been reported by various law enforcement since </del>2018 . <del class="diffchange diffchange-inline">However</del>, <del class="diffchange diffchange-inline">most of </del>the <del class="diffchange diffchange-inline">SCBs are full agonists at CB1 and CB2 receptors</del>, <del class="diffchange diffchange-inline">having a higher risk of undesirable side effects when compared to THC </del>which is <del class="diffchange diffchange-inline">a partial agonist </del>. <del class="diffchange diffchange-inline">Synthetic cannabinoids (SCBs) are agonists at cannabinoid receptor type </del>1 <del class="diffchange diffchange-inline">(CB1) and type 2 (CB2)</del>, <del class="diffchange diffchange-inline">where they elicit their main effect</del>&lt;br&gt;&lt;br&gt;&lt;br&gt;The <del class="diffchange diffchange-inline">% peak area abundance ratio of metabolites detected in the urine samples are often affected by numerous factors such as drug intake behaviour (intake route, amount of drug and intake frequency), time from last drug intake and metabolic stability. This indicated that the phase I metabolism of 4F-MDMB-BINACA are unlikely </del>to <del class="diffchange diffchange-inline">be affected significantly by polydrug intake. Oxidative defluorination with subsequent butanoic acid formation (B17) metabolite, </del>the <del class="diffchange diffchange-inline">second major metabolite after monohydroxylation in the C</del>. <del class="diffchange diffchange-inline">Ester hydrolysis with dehydrogenation formed in-vivo in this study </del>was <del class="diffchange diffchange-inline">also reported among other indazole carboxamide type SCBs with tert-leucine methyl ester moieties such </del>as <del class="diffchange diffchange-inline">5F-MDMB-PINACA and MDMB-4en-PINACA [39, 40]</del>. <del class="diffchange diffchange-inline">Similar to </del>the <del class="diffchange diffchange-inline">in-vivo findings, 4F-MDMB-BINACA ester hydrolysis (B22) was the major metabolite </del>for <del class="diffchange diffchange-inline">both HepG2 and HLM models, consistent with the known hydrolytic activity </del>of <del class="diffchange diffchange-inline">CES reported</del></div></td><td class='diff-marker'>+</td><td style="color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>After the incubation, mixture was centrifuged (18,000 x g, 20 °C) for 5 min and 0.5 μL of the supernatant was directly injected to the chromatographic system. In the next step, ammonium formate as salting agent was added to the mixture and incubated in a thermomixer (20 °C, 1200 rpm) for 15 min. After vortex-mixing, the mixture was allowed to stand <ins class="diffchange diffchange-inline">5CLADBA </ins>at room temperature for 5 min. MS/MS experiments were performed in MRM (multiple reaction monitoring) mode with an isolation window of 0.4 m/z. The MS measurement was performed in positive ion mode (except for some acidic compounds such as barbiturates&lt;br&gt;&lt;br&gt;<ins class="diffchange diffchange-inline">The % peak area abundance ratio of metabolites </ins>detected <ins class="diffchange diffchange-inline">in the urine samples are often affected by numerous factors such as drug intake behaviour (intake route</ins>, <ins class="diffchange diffchange-inline">amount of drug </ins>and <ins class="diffchange diffchange-inline">intake frequency</ins>)<ins class="diffchange diffchange-inline">, time from last drug intake </ins>and <ins class="diffchange diffchange-inline">metabolic stabilit&lt;br&gt;&lt;br&gt;&lt;br&gt;LC</ins>-<ins class="diffchange diffchange-inline">QTOF</ins>-<ins class="diffchange diffchange-inline">MS represents a significant advancement in </ins>the <ins class="diffchange diffchange-inline">field </ins>of <ins class="diffchange diffchange-inline">drug detection, offering higher sensitivity</ins>, <ins class="diffchange diffchange-inline">specificity</ins>, <ins class="diffchange diffchange-inline">and </ins>a <ins class="diffchange diffchange-inline">broader spectrum </ins>of <ins class="diffchange diffchange-inline">detectable substances</ins>. <ins class="diffchange diffchange-inline">Despite all negative results in </ins>the <ins class="diffchange diffchange-inline">point-</ins>of<ins class="diffchange diffchange-inline">-care test for recreational drugs</ins>, the <ins class="diffchange diffchange-inline">liquid chromatography-quadrupole time</ins>-<ins class="diffchange diffchange-inline">of-flight mass spectrometry </ins>(<ins class="diffchange diffchange-inline">LC-QTOF-MS</ins>) <ins class="diffchange diffchange-inline">analysis showed that the liquid of the e-cigarette contained ADB-BUTINACA</ins>, <ins class="diffchange diffchange-inline">a synthetic cannabinoid</ins>. <ins class="diffchange diffchange-inline">We report </ins>a <ins class="diffchange diffchange-inline">27-year-old man who was admitted to </ins>the <ins class="diffchange diffchange-inline">emergency room because </ins>of <ins class="diffchange diffchange-inline">sudden 5CLADBA headache, nausea, vertigo, red eyes and palpitations. Synthetic cannabinoids are gaining popularity globally and detection is not commonly available</ins>.&lt;br&gt;<ins class="diffchange diffchange-inline">Data availability </ins>&lt;br&gt;<ins class="diffchange diffchange-inline">When clinical presentation and</ins>/<ins class="diffchange diffchange-inline">or initial DOA testing results are inconclusive</ins>, <ins class="diffchange diffchange-inline">additional testing with LC-QTOF-MS can be valuable and is recommended. SCRAs and other NPS may not be detected by point</ins>-<ins class="diffchange diffchange-inline">of</ins>-<ins class="diffchange diffchange-inline">care DOA tests. In this case</ins>, the <ins class="diffchange diffchange-inline">point-</ins>of<ins class="diffchange diffchange-inline">-care DOA urine screening was not able to detect the synthetic cannabinoid ADB-BUTINAC&lt;br&gt;&lt;br&gt;4</ins>. <ins class="diffchange diffchange-inline">Drugs &lt;br&gt;In general, </ins>the <ins class="diffchange diffchange-inline">locomotor depressant and discriminative stimulus effects have been observed at doses that do not produce adverse effects, although tremors were observed upon handling </ins>in <ins class="diffchange diffchange-inline">mice that received JWH-210 (Gatch et al</ins>., <ins class="diffchange diffchange-inline">2016)</ins>, and <ins class="diffchange diffchange-inline">5F-AMB produced sustained vocalization and convulsions in rats </ins>(<ins class="diffchange diffchange-inline">Gatch et al</ins>.<ins class="diffchange diffchange-inline">, 2018</ins>). <ins class="diffchange diffchange-inline">All of the synthetic cannabinoids tested </ins>in <ins class="diffchange diffchange-inline">the present study fully substituted for the discriminative stimulus effects of Δ9-THC. Subsequently, a one</ins>-<ins class="diffchange diffchange-inline">way analysis </ins>of <ins class="diffchange diffchange-inline">variance was conducted </ins>on <ins class="diffchange diffchange-inline">horizontal activity counts for </ins>the <ins class="diffchange diffchange-inline">30-min period </ins>of <ins class="diffchange diffchange-inline">maximal effect</ins>, and <ins class="diffchange diffchange-inline">planned comparisons were conducted for each dose against the vehicle control using single degree-of-freedom F tests</ins>. <ins class="diffchange diffchange-inline">A two</ins>-<ins class="diffchange diffchange-inline">way analysis </ins>of <ins class="diffchange diffchange-inline">variance, </ins>with <ins class="diffchange diffchange-inline">dose as a between groups factor and time as a within subject factor</ins>, <ins class="diffchange diffchange-inline">was conducted on horizontal activity counts/10 min interval. Locomotor activity in mice was tested to screen for locomotor depressant effects and to identify behaviorally</ins>-<ins class="diffchange diffchange-inline">active dose ranges </ins>and <ins class="diffchange diffchange-inline">times of peak effect. Previous studies have demonstrated that these compounds have chemical structures similar to synthetic cannabinoids known </ins>to <ins class="diffchange diffchange-inline">have substantial abuse liability and act at the CB1 receptor</ins>.&lt;br&gt;<ins class="diffchange diffchange-inline">Michael B Gatch </ins>&lt;br&gt;<ins class="diffchange diffchange-inline">Substantial depressant effects were observed within the first 10 min, and maximal depression </ins>was <ins class="diffchange diffchange-inline">observed between 0–30 min following administration. Tremors were observed 30 minutes following 1 mg/kg AMB</ins>-<ins class="diffchange diffchange-inline">FUBINACA in 3 of 8 mice (data not shown). Substantial depressant effects were observed within the first 10 min, and maximal depression was observed between 10–40 min and lasted up to 2.5 to 3 h at the </ins>[https://cannabinoidsrc4f-adb.com/ <ins class="diffchange diffchange-inline">5CLADBA] highest dose tested (0.5 mg</ins>/<ins class="diffchange diffchange-inline">kg).&lt;br&gt;Figure 1</ins>. <ins class="diffchange diffchange-inline">&lt;br&gt;There is indication that at least some of </ins>the <ins class="diffchange diffchange-inline">first-generation synthetic cannabinoids act at receptors other than cannabinoid CB1 </ins>and <ins class="diffchange diffchange-inline">CB2 (Wiley et al</ins>., <ins class="diffchange diffchange-inline">2016</ins>), and <ins class="diffchange diffchange-inline">a compound from the present study, 5F-MDMB</ins>-<ins class="diffchange diffchange-inline">PINACA</ins>, <ins class="diffchange diffchange-inline">was </ins>found <ins class="diffchange diffchange-inline">to activate midbrain dopamine neurons, but not serotonin neurons </ins>(<ins class="diffchange diffchange-inline">Asaoka et al., 2016</ins>). <ins class="diffchange diffchange-inline">As previously mentioned</ins>, <ins class="diffchange diffchange-inline">all </ins>of the <ins class="diffchange diffchange-inline">compounds tested in </ins>the <ins class="diffchange diffchange-inline">present study </ins>(<ins class="diffchange diffchange-inline">MDMB</ins>-<ins class="diffchange diffchange-inline">PINACA, MDMB</ins>-<ins class="diffchange diffchange-inline">CHMICA</ins>, MDMB-<ins class="diffchange diffchange-inline">FUBINACA</ins>, <ins class="diffchange diffchange-inline">ADB</ins>-<ins class="diffchange diffchange-inline">FUBINACA, and AMB</ins>-<ins class="diffchange diffchange-inline">FUBINACA</ins>) <ins class="diffchange diffchange-inline">act as agonists at CB1 receptors (Banister et al.</ins>, <ins class="diffchange diffchange-inline">2015, 2016; Gamage et al.</ins>, 2018<ins class="diffchange diffchange-inline">), which suggests these compounds will produce Δ9-THC-like effects, including abuse liability</ins>. <ins class="diffchange diffchange-inline">Tremors were not observed following AMB-FUBINACA during the drug discrimination study</ins>, <ins class="diffchange diffchange-inline">but </ins>the <ins class="diffchange diffchange-inline">maximum dose tested was only 0.1 mg/kg</ins>, which is <ins class="diffchange diffchange-inline">10-fold lower than the dose that produced tremors in the mic&lt;br&gt;&lt;br&gt;Tremors were not observed following AMB-FUBINACA during the drug discrimination study, but the maximum dose tested was only 0</ins>.1 <ins class="diffchange diffchange-inline">mg/kg</ins>, <ins class="diffchange diffchange-inline">which is 10-fold lower than the dose that produced tremors in the mic</ins>&lt;br&gt;&lt;br&gt;&lt;br&gt;The <ins class="diffchange diffchange-inline">same procedure was then applied </ins>to the <ins class="diffchange diffchange-inline">mice once every day for 5 days</ins>. <ins class="diffchange diffchange-inline">It </ins>was <ins class="diffchange diffchange-inline">considered </ins>as <ins class="diffchange diffchange-inline">coordination disturbance when mice fell from the test apparatus within 2 min</ins>. <ins class="diffchange diffchange-inline">Mice that remained their position on </ins>the <ins class="diffchange diffchange-inline">running apparatus at 10 rpm for at least 2 min were selected </ins>for <ins class="diffchange diffchange-inline">further evaluation.&lt;br&gt;Table </ins>of <ins class="diffchange diffchange-inline">Conten</ins></div></td></tr> <!-- diff cache key stadtwiki:diff::1.12:old-28602:rev-28604 --> </table>

DianeDevries https://www.stadtwiki-strausberg.de/index.php?title=5F-ADB_Wikipedia&diff=28602&oldid=prev 2026-06-04T08:44:46Z

<p></p> <table class="diff diff-contentalign-left" data-mw="interface"> <col class="diff-marker" /> <col class="diff-content" /> <col class="diff-marker" /> <col class="diff-content" /> <tr class="diff-title" lang="de"> <td colspan="2" style="background-color: #fff; color: #222; text-align: center;">← Nächstältere Version</td> <td colspan="2" style="background-color: #fff; color: #222; text-align: center;">Version vom 4. Juni 2026, 08:44 Uhr</td> </tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l1" >Zeile 1:</td> <td colspan="2" class="diff-lineno">Zeile 1:</td></tr> <tr><td class='diff-marker'>−</td><td style="color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del class="diffchange diffchange-inline">To evaluate whether </del>the <del class="diffchange diffchange-inline">changes </del>of <del class="diffchange diffchange-inline">coordinative functions by CNS damages were due to test substances, rota</del>-<del class="diffchange diffchange-inline">rod test was performed using Rota</del>-<del class="diffchange diffchange-inline">rod apparatus (Daejong</del>, <del class="diffchange diffchange-inline">Seoul</del>, <del class="diffchange diffchange-inline">Korea)</del>. <del class="diffchange diffchange-inline">The test apparatus for </del>the <del class="diffchange diffchange-inline">locomotor activity test was designed </del>to <del class="diffchange diffchange-inline">measure locomotor activity automatically using UV system (AM 1051</del>, <del class="diffchange diffchange-inline">Benwick Electronics, Benwick, UK) when experimental animals moved in </del>the <del class="diffchange diffchange-inline">chamber. In both tests, a group </del>of <del class="diffchange diffchange-inline">mice were treated with negative control (vehicle, 1 mg</del>/<del class="diffchange diffchange-inline">kg, i</del>.<del class="diffchange diffchange-inline">p.), positive control (methamphetamine, 1 mg/kg</del>, <del class="diffchange diffchange-inline">i</del>.<del class="diffchange diffchange-inline">p</del>.<del class="diffchange diffchange-inline">), or one </del>of <del class="diffchange diffchange-inline">the three doses of test substances (0</del>.<del class="diffchange diffchange-inline">1</del>, <del class="diffchange diffchange-inline">1</del>, <del class="diffchange diffchange-inline">5 mg/kg</del>, <del class="diffchange diffchange-inline">i.p.) once every other day for 10 day&lt;br&gt;&lt;br&gt;Synthetic cannabinoids have consistently been shown </del>to <del class="diffchange diffchange-inline">produce discriminative stimulus effects similar to those of Δ9-THC </del>(<del class="diffchange diffchange-inline">Bannister and Connor, 2018</del>)<del class="diffchange diffchange-inline">, and MDMB-FUBINACA fully substituted for Δ9-THC (Gamage et al</del>.<del class="diffchange diffchange-inline">, 2018</del>&lt;br&gt;&lt;br&gt;&lt;br&gt;<del class="diffchange diffchange-inline">Buy Jwh-210 at USA K2 INCENSE STORE and enjoy premium quality, flexible quantities, and fast, secure shipping. Fast shipping and pure product-highly recommended for anyone needing quality incense ingredients.&quot; 🌟🌟🌟🌟🌟 You can buy jwh-210 online in quantities of JWH-210 powder 10g, 30g, 50g, 100g, 150g, and 200g at USA K2 INCENSE STORE for premium quality and discreet shipping. In some areas, it is classified as a controlled substance, while in others, it may be legal for research or incense use. The legal status of jwh-210 varies by country and region.</del>&lt;br&gt; <del class="diffchange diffchange-inline">Key Features and Specifications to Evaluate &lt;br&gt;In case of cannabis or Δ9-tetrahydrocannabinol</del>, <del class="diffchange diffchange-inline">there are many JWH-210 powder previous studies regarding with their dependence potential and neurotoxicity </del>(<del class="diffchange diffchange-inline">Cororan</del>, <del class="diffchange diffchange-inline">et al.</del>, <del class="diffchange diffchange-inline">1974; Harris, et al., 1974; Leite and Culini, 1974; Hutcheson, et al., 1998</del>)<del class="diffchange diffchange-inline">. After administering test substances once every other day </del>for <del class="diffchange diffchange-inline">10 days, brain samples of mice were collected, especially at nucleus accumbens </del>and <del class="diffchange diffchange-inline">hippocampus regions</del>. <del class="diffchange diffchange-inline">Drug was administered </del>5 <del class="diffchange diffchange-inline">times every other day, and </del>the <del class="diffchange diffchange-inline">first trial </del>was <del class="diffchange diffchange-inline">performed 2 h after </del>the <del class="diffchange diffchange-inline">last administration</del>.<del class="diffchange diffchange-inline">&lt;br&gt; How to Choose Powder JWH-210 &lt;br&gt;This dual-use nature underscores </del>the <del class="diffchange diffchange-inline">importance of responsible sourcing and strict adherence to legal frameworks. Forensic labs</del>, <del class="diffchange diffchange-inline">public health researchers, and customs officials use authentic samples like JWH-210 </del>to <del class="diffchange diffchange-inline">distinguish between legal </del>and <del class="diffchange diffchange-inline">illegal compounds </del>in <del class="diffchange diffchange-inline">seized materials. For those seeking </del>a <del class="diffchange diffchange-inline">dependable compound </del>for <del class="diffchange diffchange-inline">analytical purposes, JWH-210 Chemical Powder provides a trusted and effective solution</del>. <del class="diffchange diffchange-inline">With its carefully controlled production process, stable composition, and secure packaging, it remains a valuable resource for laboratory</del>-<del class="diffchange diffchange-inline">based researc&lt;br&gt;&lt;br&gt; In histopathological analysis</del>, <del class="diffchange diffchange-inline">neural cells of </del>the <del class="diffchange diffchange-inline">animals treated with the high dose (5 mg</del>/<del class="diffchange diffchange-inline">kg) of JWH-081 or JWH-210 showed distorted nuclei and nucleus membranes in the core shell of nucleus accumbens, suggesting neurotoxicit&lt;br&gt;&lt;br&gt; The findings produce an apparent paradox, since CPP and self-administration predict with high reliability the likelihood that a compound will be abused by humans, and cannabinoids are well-known to produce active drug-seeking in human&lt;br&gt;&lt;br&gt;&lt;br&gt;When clinical presentation and</del>/<del class="diffchange diffchange-inline">or initial DOA testing results are inconclusive, additional testing with LC-QTOF</del>-<del class="diffchange diffchange-inline">MS can be valuable and is recommended</del>. <del class="diffchange diffchange-inline">SCRAs and other NPS may not be detected by point-of-care DOA tests</del>. <del class="diffchange diffchange-inline">In this case, the point-of-care DOA urine screening was not able to detect the synthetic cannabinoid ADB-BUTINAC&lt;br&gt;&lt;br&gt;&lt;br&gt;Effects of individual doses </del>were <del class="diffchange diffchange-inline">compared to the vehicle control value using a priori contrasts. Response-rate data were analyzed by one-way repeated-measure analysis </del>of <del class="diffchange diffchange-inline">variance</del>. <del class="diffchange diffchange-inline">Percent drug-appropriate responding was shown only if at [https:</del>/<del class="diffchange diffchange-inline">/cannabinoidsrc4f-adb</del>.<del class="diffchange diffchange-inline">com/ JWH-210 powder] least three rats completed the first fixed ratio, whereas all rats are shown </del>for <del class="diffchange diffchange-inline">the response rate dat</del>&lt;br&gt;&lt;br&gt;&lt;br&gt;Product ions detected at m/z 302, 217, and 145 (B2) confirmed that tert-leucine and indazole moieties remained unchanged, leading to the structure elucidation of a hydroxy-functional group at the 4-position of the butyl side chain by oxidative defluorination. The product ion m/z 336 (loss of methyl ester moiety) further confirmed the presence of dihydroxylated metabolites. The precursor ion, m/z 364 (B14, B5/B6) had a loss of 2 Da from m/z 366 indicated further dehydrogenation of the ester hydrolysis plus monohydroxylated metabolites. The presence of the product ion m/z 320, likely formed from a loss of carbon dioxide, indicated monohydroxylation at the tert-leucine in B8 (m/z 219), butyl side chain in B9 (m/z 145) and indazole moiety in B13 (m/z 161). The precursor ion, m/z 350 showed a loss of 14 Da explaining the hydrolysis of methyl ester from 4F-MDMB-BINACA.&lt;br&gt; Fig. 2. &lt;br&gt;The precursor ion m/z 396 (B10, B12/B15) was 32 Da higher than the parent drug, 4F-MDMB-BINACA, suggesting the addition of two hydroxy groups. All the below explanations for transformations into metabolites are based on the data shown in Fig. Metabolites were identified according to their precursor ions, product ions, and fragmentation patterns (Fig. 1). Traditional in-vivo metabolism studies to generate human metabolites of drugs relied heavily on the use of whole animal model systems, which are expensive, limited by drug administration amount, influenced by species variation and faced by many ethical issues. Eight in-vivo metabolites tentatively identified were mainly products of ester hydrolysis with or without additional dehydrogenation, N-dealkylation, monohydroxylation and oxidative defluorination with further oxidation to butanoic acid.&lt;br&gt; Fig. 1. &lt;br&gt;<del class="diffchange diffchange-inline">Monitoring metabolism of synthetic cannabinoid 4F</del>-<del class="diffchange diffchange-inline">MDMB</del>-<del class="diffchange diffchange-inline">BINACA via high</del>-<del class="diffchange diffchange-inline">resolution mass spectrometry assessed in cultured hepatoma cell line, fungus, JWH-210 powder liver microsomes </del>and <del class="diffchange diffchange-inline">confirmed using urine </del>samples <del class="diffchange diffchange-inline">The threshold for fatal overdose of combined use of SCRAs and ethanol can be estimated as a little ng/mL </del>(<del class="diffchange diffchange-inline">0.37–4.1 ng</del>/<del class="diffchange diffchange-inline">mL according to the reported cases</del>) <del class="diffchange diffchange-inline">of SCRA and 1</del>.<del class="diffchange diffchange-inline">5–2.5 g</del>/<del class="diffchange diffchange-inline">L of ethanol. The reported cases </del>and <del class="diffchange diffchange-inline">reviews of the scientific literature suggest a possible synergistic effect between SCRAs and ethanol</del>, <del class="diffchange diffchange-inline">because their combined use clearly increases their toxicity</del>. <del class="diffchange diffchange-inline">The victim died due to severe necrotizing pancreatitis and acute kidney injury evolving into multi</del>-<del class="diffchange diffchange-inline">organ failure 11 days after hospital admission </del>. <del class="diffchange diffchange-inline">Studies have found no unequivocal synergistic effect between THC and ethanol </del>at <del class="diffchange diffchange-inline">low or moderate ethanol doses [29</del>, <del class="diffchange diffchange-inline">30]</del>, <del class="diffchange diffchange-inline">but no data on high doses </del>of <del class="diffchange diffchange-inline">ethanol are available. Given that THC and ethanol act on </del>the <del class="diffchange diffchange-inline">same receptors, data on their simultaneous use may yield important insights in this regard</del>.&lt;br&gt; Fungus C. elegans &lt;br&gt;<del class="diffchange diffchange-inline">Concentrations of </del>4F-MDMB-BINACA in the <del class="diffchange diffchange-inline">postmortem blood samples were 2</del>.<del class="diffchange diffchange-inline">50 </del>and 2<del class="diffchange diffchange-inline">.34 ng/mL</del>, <del class="diffchange diffchange-inline">which </del>are <del class="diffchange diffchange-inline">in line with published data</del>. <del class="diffchange diffchange-inline">Although </del>the <del class="diffchange diffchange-inline">lethal dose </del>of 4F-MDMB-BINACA <del class="diffchange diffchange-inline">is unknown</del>, <del class="diffchange diffchange-inline">its concentration </del>in <del class="diffchange diffchange-inline">postmortem blood samples </del>was <del class="diffchange diffchange-inline">found to range between 0.10 </del>and <del class="diffchange diffchange-inline">2.90 ng/mL . In SCRA</del>-<del class="diffchange diffchange-inline">related cases in which the deceased suffered from heart disease</del>, the <del class="diffchange diffchange-inline">SCRA concentration </del>in the <del class="diffchange diffchange-inline">postmortem blood was less than 1 ng/mL . Concentrations of SCRAs in postmortem cases cover a wide range ; however</del>, <del class="diffchange diffchange-inline">some reports </del>of <del class="diffchange diffchange-inline">survival have also been published—even at relatively high blood SCRA concentrations [19, 20</del></div></td><td class='diff-marker'>+</td><td style="color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins class="diffchange diffchange-inline">LC separates </ins>the <ins class="diffchange diffchange-inline">urine or blood sample and QTOF-MS provides high-resolution and accurate mass measurements for precise identification and structural elucidation </ins>of <ins class="diffchange diffchange-inline">compounds. The LC</ins>-<ins class="diffchange diffchange-inline">QTOF</ins>-<ins class="diffchange diffchange-inline">MS method offers a more comprehensive and sensitive approach for drug detection</ins>, <ins class="diffchange diffchange-inline">covering hundreds of recreational drugs</ins>, <ins class="diffchange diffchange-inline">including NPS</ins>. <ins class="diffchange diffchange-inline">Besides increasing </ins>the <ins class="diffchange diffchange-inline">temperature </ins>to <ins class="diffchange diffchange-inline">enlarge the drug aerolisation and bioavailability</ins>, <ins class="diffchange diffchange-inline">one can elevate </ins>the <ins class="diffchange diffchange-inline">flow rate </ins>of <ins class="diffchange diffchange-inline">air through the e-cigarette and</ins>/<ins class="diffchange diffchange-inline">or add a diluent </ins>. <ins class="diffchange diffchange-inline">Of all e-cigarette users registered at this forum</ins>, <ins class="diffchange diffchange-inline">7</ins>.<ins class="diffchange diffchange-inline">8 % vaped SCRAs </ins>. <ins class="diffchange diffchange-inline">About 15 % </ins>of <ins class="diffchange diffchange-inline">individuals registered at forums for drug users such as erowid.org who vaped cannabis have also vaped SRCAs</ins>. <ins class="diffchange diffchange-inline">SCRAs belong</ins>, <ins class="diffchange diffchange-inline">together with synthetic opioids</ins>, <ins class="diffchange diffchange-inline">cathinones</ins>, <ins class="diffchange diffchange-inline">amphetamines and hallucinogens </ins>to <ins class="diffchange diffchange-inline">the new psychoactive substances </ins>(<ins class="diffchange diffchange-inline">NPS</ins>) <ins class="diffchange diffchange-inline">that are currently developed at high speed</ins>.&lt;br&gt;<ins class="diffchange diffchange-inline">Data availabili</ins>&lt;br&gt;&lt;br&gt;&lt;br&gt;<ins class="diffchange diffchange-inline">After the incubation</ins>, <ins class="diffchange diffchange-inline">mixture was centrifuged </ins>(<ins class="diffchange diffchange-inline">18</ins>,<ins class="diffchange diffchange-inline">000 x g</ins>, <ins class="diffchange diffchange-inline">20 °C</ins>) for <ins class="diffchange diffchange-inline">5 min </ins>and <ins class="diffchange diffchange-inline">0</ins>.5 <ins class="diffchange diffchange-inline">μL of </ins>the <ins class="diffchange diffchange-inline">supernatant </ins>was <ins class="diffchange diffchange-inline">directly injected to </ins>the <ins class="diffchange diffchange-inline">chromatographic system</ins>. <ins class="diffchange diffchange-inline">In </ins>the <ins class="diffchange diffchange-inline">next step</ins>, <ins class="diffchange diffchange-inline">ammonium formate as salting agent was added </ins>to <ins class="diffchange diffchange-inline">the mixture </ins>and <ins class="diffchange diffchange-inline">incubated </ins>in a <ins class="diffchange diffchange-inline">thermomixer (20 °C, 1200 rpm) </ins>for <ins class="diffchange diffchange-inline">15 min</ins>. <ins class="diffchange diffchange-inline">After vortex</ins>-<ins class="diffchange diffchange-inline">mixing</ins>, the <ins class="diffchange diffchange-inline">mixture was allowed to stand Https:</ins>//<ins class="diffchange diffchange-inline">Cannabinoidsrc4F</ins>-<ins class="diffchange diffchange-inline">Adb</ins>.<ins class="diffchange diffchange-inline">Com/ at room temperature for 5 min</ins>. <ins class="diffchange diffchange-inline">MS/MS experiments </ins>were <ins class="diffchange diffchange-inline">performed in MRM (multiple reaction monitoring) mode with an isolation window </ins>of <ins class="diffchange diffchange-inline">0</ins>.<ins class="diffchange diffchange-inline">4 m</ins>/<ins class="diffchange diffchange-inline">z</ins>. <ins class="diffchange diffchange-inline">The MS measurement was performed in positive ion mode (except </ins>for <ins class="diffchange diffchange-inline">some acidic compounds such as barbiturates</ins>&lt;br&gt;&lt;br&gt;&lt;br&gt;Product ions detected at m/z 302, 217, and 145 (B2) confirmed that tert-leucine and indazole moieties remained unchanged, leading to the structure elucidation of a hydroxy-functional group at the 4-position of the butyl side chain by oxidative defluorination. The product ion m/z 336 (loss of methyl ester moiety) further confirmed the presence of dihydroxylated metabolites. The precursor ion, m/z 364 (B14, B5/B6) had a loss of 2 Da from m/z 366 indicated further dehydrogenation of the ester hydrolysis plus monohydroxylated metabolites. The presence of the product ion m/z 320, likely formed from a loss of carbon dioxide, indicated monohydroxylation at the tert-leucine in B8 (m/z 219), butyl side chain in B9 (m/z 145) and indazole moiety in B13 (m/z 161). The precursor ion, m/z 350 showed a loss of 14 Da explaining the hydrolysis of methyl ester from 4F-MDMB-BINACA.&lt;br&gt;Fig. 2. &lt;br&gt;The precursor ion m/z 396 (B10, B12/B15) was 32 Da higher than the parent drug, 4F-MDMB-BINACA, suggesting the addition of two hydroxy groups. All the below explanations for transformations into metabolites are based on the data shown in Fig. Metabolites were identified according to their precursor ions, product ions, and fragmentation patterns (Fig. 1). Traditional in-vivo metabolism studies to generate human metabolites of drugs relied heavily on the use of whole animal model systems, which are expensive, limited by drug administration amount, influenced by species variation and faced by many ethical issues. Eight in-vivo metabolites tentatively identified were mainly products of ester hydrolysis with or without additional dehydrogenation, N-dealkylation, monohydroxylation and oxidative defluorination with further oxidation to butanoic acid.&lt;br&gt;Fig. 1. &lt;br&gt;<ins class="diffchange diffchange-inline">This outcome was anticipated since CES</ins>-<ins class="diffchange diffchange-inline">mediated hydrolysis is commonly [https://cannabinoidsrc4f</ins>-<ins class="diffchange diffchange-inline">adb.com/ Https://Cannabinoidsrc4F</ins>-<ins class="diffchange diffchange-inline">Adb.Com/] reported as the major metabolic pathway among the SCBs impacting the terminal ester group . Glucosides </ins>and <ins class="diffchange diffchange-inline">sulfate metabolites have been reported with other SCBs where C. From these three </ins>samples<ins class="diffchange diffchange-inline">, sample 2 contained only an ester hydrolysis metabolite </ins>(<ins class="diffchange diffchange-inline">m</ins>/<ins class="diffchange diffchange-inline">z 350</ins>). <ins class="diffchange diffchange-inline">Both ester hydrolysis followed by oxidative defluorination to butanoic acid (B4, m</ins>/<ins class="diffchange diffchange-inline">z 362) </ins>and <ins class="diffchange diffchange-inline">monohydroxylation at tert-leucine moiety (B8</ins>, <ins class="diffchange diffchange-inline">m/z 366) metabolites were found in 16/20 urine samples (Table 2)</ins>. <ins class="diffchange diffchange-inline">A In</ins>-<ins class="diffchange diffchange-inline">vitro metabolites observed in common among respective seven most abundant metabolites in b C</ins>. <ins class="diffchange diffchange-inline">The product ion detected </ins>at <ins class="diffchange diffchange-inline">m/z 235</ins>, <ins class="diffchange diffchange-inline">indicating loss of sulfate</ins>, <ins class="diffchange diffchange-inline">confirmed the identity </ins>of the <ins class="diffchange diffchange-inline">sulfation metabolite</ins>.&lt;br&gt;Fungus C. elegans &lt;br&gt;<ins class="diffchange diffchange-inline">Methyl (2S)-2-([1-(4-fluorobutyl)-1H-indazole-3-carbonyl]amino)-3,3-dimethylbutanoate (</ins>4F-MDMB-BINACA<ins class="diffchange diffchange-inline">, 4F-MDMB-BUTINACA or 4F-ADB), found </ins>in <ins class="diffchange diffchange-inline">numerous SCB product seizures, has been reported by various law enforcement since 2018 . However, most of </ins>the <ins class="diffchange diffchange-inline">SCBs are full agonists at CB1 and CB2 receptors, having a higher risk of undesirable side effects when compared to THC which is a partial agonist </ins>. <ins class="diffchange diffchange-inline">Synthetic cannabinoids (SCBs) are agonists at cannabinoid receptor type 1 (CB1) </ins>and <ins class="diffchange diffchange-inline">type </ins>2 <ins class="diffchange diffchange-inline">(CB2)</ins>, <ins class="diffchange diffchange-inline">where they elicit their main effect&lt;br&gt;&lt;br&gt;&lt;br&gt;The % peak area abundance ratio of metabolites detected in the urine samples </ins>are <ins class="diffchange diffchange-inline">often affected by numerous factors such as drug intake behaviour (intake route, amount of drug and intake frequency), time from last drug intake and metabolic stability</ins>. <ins class="diffchange diffchange-inline">This indicated that </ins>the <ins class="diffchange diffchange-inline">phase I metabolism </ins>of 4F-MDMB-BINACA <ins class="diffchange diffchange-inline">are unlikely to be affected significantly by polydrug intake. Oxidative defluorination with subsequent butanoic acid formation (B17) metabolite</ins>, <ins class="diffchange diffchange-inline">the second major metabolite after monohydroxylation in the C. Ester hydrolysis with dehydrogenation formed </ins>in<ins class="diffchange diffchange-inline">-vivo in this study </ins>was <ins class="diffchange diffchange-inline">also reported among other indazole carboxamide type SCBs with tert-leucine methyl ester moieties such as 5F-MDMB-PINACA </ins>and <ins class="diffchange diffchange-inline">MDMB-4en</ins>-<ins class="diffchange diffchange-inline">PINACA [39</ins>, <ins class="diffchange diffchange-inline">40]. Similar to </ins>the in<ins class="diffchange diffchange-inline">-vivo findings, 4F-MDMB-BINACA ester hydrolysis (B22) was </ins>the <ins class="diffchange diffchange-inline">major metabolite for both HepG2 and HLM models</ins>, <ins class="diffchange diffchange-inline">consistent with the known hydrolytic activity </ins>of <ins class="diffchange diffchange-inline">CES reported</ins></div></td></tr> <!-- diff cache key stadtwiki:diff::1.12:old-28425:rev-28602 --> </table>

ScarlettCagle66 https://www.stadtwiki-strausberg.de/index.php?title=5F-ADB_Wikipedia&diff=28425&oldid=prev 2026-06-01T17:18:37Z

<p></p> <table class="diff diff-contentalign-left" data-mw="interface"> <col class="diff-marker" /> <col class="diff-content" /> <col class="diff-marker" /> <col class="diff-content" /> <tr class="diff-title" lang="de"> <td colspan="2" style="background-color: #fff; color: #222; text-align: center;">← Nächstältere Version</td> <td colspan="2" style="background-color: #fff; color: #222; text-align: center;">Version vom 1. Juni 2026, 17:18 Uhr</td> </tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l1" >Zeile 1:</td> <td colspan="2" class="diff-lineno">Zeile 1:</td></tr> <tr><td class='diff-marker'>−</td><td style="color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del class="diffchange diffchange-inline">In </del>the <del class="diffchange diffchange-inline">present study</del>, <del class="diffchange diffchange-inline">we </del>performed <del class="diffchange diffchange-inline">various methods based on animal behavioral testing including FOB </del>test for <del class="diffchange diffchange-inline">general behavioral observation, rotarod </del>test<del class="diffchange diffchange-inline">, </del>locomotor activity <del class="diffchange diffchange-inline">test for motor function evaluation</del>, <del class="diffchange diffchange-inline">and water-maze test for learning/memory evaluation. Known for its stability and consistent composition</del>, <del class="diffchange diffchange-inline">this compound is frequently utilized by professionals seeking reliable materials for laboratory-based analytical studies</del>. In <del class="diffchange diffchange-inline">this study</del>, <del class="diffchange diffchange-inline">histopathological evaluation was performed to confirm the possibility </del>of <del class="diffchange diffchange-inline">neurotoxicity of the tested substances by hematoxylin and eosin staining method from collected brain samples</del>. <del class="diffchange diffchange-inline">In the present study</del>, <del class="diffchange diffchange-inline">we evaluated the neurotoxicity of two synthetic cannabinoids </del>(<del class="diffchange diffchange-inline">JWH-081 and JWH-210</del>) <del class="diffchange diffchange-inline">through observation </del>of <del class="diffchange diffchange-inline">various behavioral changes and analysis </del>of <del class="diffchange diffchange-inline">histopathological changes using experimental mice with various doses </del>(0.1, 1, 5 mg/kg<del class="diffchange diffchange-inline">)</del>. <del class="diffchange diffchange-inline">Selecting powder JWH-210 demands careful evaluation of purity, legality, and supplier credibility</del>. <del class="diffchange diffchange-inline">Prices </del>for <del class="diffchange diffchange-inline">research-grade JWH-210 vary significantly based on quantity, purity, and vendor complianc</del>&lt;br&gt;&lt;br&gt;<del class="diffchange diffchange-inline">4. Drugs &lt;br&gt;In general, the locomotor depressant and discriminative stimulus effects </del>have been <del class="diffchange diffchange-inline">observed at doses that do not </del>produce <del class="diffchange diffchange-inline">adverse </del>effects<del class="diffchange diffchange-inline">, although tremors were observed upon handling in mice that received JWH</del>-<del class="diffchange diffchange-inline">210 </del>(<del class="diffchange diffchange-inline">Gatch et al.</del>, <del class="diffchange diffchange-inline">2016</del>), and <del class="diffchange diffchange-inline">5F</del>-<del class="diffchange diffchange-inline">AMB produced sustained vocalization and convulsions in rats </del>(<del class="diffchange diffchange-inline">Gatch </del>et al., 2018<del class="diffchange diffchange-inline">)</del>. <del class="diffchange diffchange-inline">All of the synthetic cannabinoids tested in the present study fully substituted </del>for <del class="diffchange diffchange-inline">the discriminative stimulus effects of Δ9-THC</del>. <del class="diffchange diffchange-inline">Subsequently, a one</del>-<del class="diffchange diffchange-inline">way analysis </del>of <del class="diffchange diffchange-inline">variance was conducted on horizontal activity counts for the 30</del>-<del class="diffchange diffchange-inline">min period of maximal effect</del>, and <del class="diffchange diffchange-inline">planned comparisons were conducted </del>for <del class="diffchange diffchange-inline">each dose against the vehicle control using single degree-of-freedom F tests</del>. <del class="diffchange diffchange-inline">A two-way analysis of variance</del>, <del class="diffchange diffchange-inline">with dose </del>as a <del class="diffchange diffchange-inline">between groups factor and time as a within subject factor</del>, <del class="diffchange diffchange-inline">was conducted on horizontal activity counts/10 min interval. Locomotor activity </del>in <del class="diffchange diffchange-inline">mice was tested to screen </del>for <del class="diffchange diffchange-inline">locomotor depressant effects and to identify behaviorally</del>-<del class="diffchange diffchange-inline">active dose ranges and times of peak effect. Previous studies have demonstrated that these compounds have chemical structures similar to synthetic cannabinoids known to have substantial abuse liability </del>and <del class="diffchange diffchange-inline">act at the CB1 receptor</del>.&lt;br&gt;<del class="diffchange diffchange-inline">Michael B Gatch </del>&lt;br&gt;<del class="diffchange diffchange-inline">Substantial depressant effects were observed within the first 10 min</del>, and <del class="diffchange diffchange-inline">maximal depression was observed between 0–30 min following administration</del>. <del class="diffchange diffchange-inline">Tremors were observed 30 minutes following 1 mg/kg AMB-FUBINACA in 3 </del>of <del class="diffchange diffchange-inline">8 </del>mice <del class="diffchange diffchange-inline">(data not shown). Substantial depressant effects </del>were <del class="diffchange diffchange-inline">observed within the first 10 min</del>, and <del class="diffchange diffchange-inline">maximal depression </del>was <del class="diffchange diffchange-inline">observed between 10–40 min </del>and <del class="diffchange diffchange-inline">lasted up to </del>2<del class="diffchange diffchange-inline">.5 to 3 </del>h <del class="diffchange diffchange-inline">at </del>the <del class="diffchange diffchange-inline">[https://cannabinoidsrc4f-adb.com/ Read A great deal more] highest dose tested (0.5 mg/kg)</del>.&lt;br&gt;<del class="diffchange diffchange-inline">Figure 1. </del>&lt;br&gt;<del class="diffchange diffchange-inline">There is indication that at least some </del>of <del class="diffchange diffchange-inline">the first-generation synthetic cannabinoids act at receptors other than cannabinoid CB1 </del>and <del class="diffchange diffchange-inline">CB2 (Wiley et al</del>., <del class="diffchange diffchange-inline">2016)</del>, and a compound <del class="diffchange diffchange-inline">from the present study</del>, <del class="diffchange diffchange-inline">5F</del>-<del class="diffchange diffchange-inline">MDMB-PINACA</del>, <del class="diffchange diffchange-inline">was found to activate midbrain dopamine neurons</del>, <del class="diffchange diffchange-inline">but not serotonin neurons (Asaoka et al.</del>, <del class="diffchange diffchange-inline">2016). As previously mentioned</del>, <del class="diffchange diffchange-inline">all </del>of the <del class="diffchange diffchange-inline">compounds tested in </del>the <del class="diffchange diffchange-inline">present study </del>(<del class="diffchange diffchange-inline">MDMB</del>-<del class="diffchange diffchange-inline">PINACA, MDMB</del>-<del class="diffchange diffchange-inline">CHMICA</del>, <del class="diffchange diffchange-inline">MDMB-FUBINACA</del>, <del class="diffchange diffchange-inline">ADB</del>-<del class="diffchange diffchange-inline">FUBINACA</del>, and <del class="diffchange diffchange-inline">AMB</del>-<del class="diffchange diffchange-inline">FUBINACA) act as agonists at CB1 receptors (Banister et al., 2015, 2016; Gamage et al., 2018), which suggests these compounds will </del>produce <del class="diffchange diffchange-inline">Δ9-THC-like effects, including abuse liability. Tremors were not observed following AMB-FUBINACA during the </del>drug <del class="diffchange diffchange-inline">discrimination study, but the maximum dose tested was only 0.1 mg/kg, which is 10</del>-<del class="diffchange diffchange-inline">fold lower than the dose that produced tremors </del>in <del class="diffchange diffchange-inline">the mic</del>&lt;br&gt;&lt;br&gt;&lt;br&gt;LC <del class="diffchange diffchange-inline">separates the urine or blood sample and </del>QTOF-MS <del class="diffchange diffchange-inline">provides high-resolution </del>and <del class="diffchange diffchange-inline">accurate mass measurements for precise identification </del>and <del class="diffchange diffchange-inline">structural elucidation </del>of <del class="diffchange diffchange-inline">compounds</del>. <del class="diffchange diffchange-inline">The LC</del>-<del class="diffchange diffchange-inline">QTOF</del>-<del class="diffchange diffchange-inline">MS method offers a more comprehensive and sensitive approach for drug detection, covering hundreds </del>of <del class="diffchange diffchange-inline">recreational drugs, including NPS. Besides increasing the temperature </del>to <del class="diffchange diffchange-inline">enlarge </del>the <del class="diffchange diffchange-inline">drug aerolisation and bioavailability, </del>one <del class="diffchange diffchange-inline">can elevate the flow rate </del>of <del class="diffchange diffchange-inline">air through the e</del>-<del class="diffchange diffchange-inline">cigarette and</del>/<del class="diffchange diffchange-inline">or add a diluent </del>. <del class="diffchange diffchange-inline">Of all e</del>-<del class="diffchange diffchange-inline">cigarette users registered at this forum</del>, <del class="diffchange diffchange-inline">7.8 % vaped SCRAs . About 15 % of individuals registered at forums </del>for <del class="diffchange diffchange-inline">drug users such as erowid.org who vaped cannabis have also vaped SRCAs. SCRAs belong, together with synthetic opioids, cathinones, amphetamines and hallucinogens to </del>the <del class="diffchange diffchange-inline">new psychoactive substances (NPS) that are currently developed at high speed.</del>&lt;br&gt;<del class="diffchange diffchange-inline">Data availabili</del>&lt;br&gt;&lt;br&gt;<del class="diffchange diffchange-inline">&lt;br&gt;Our findings revealed </del>that <del class="diffchange diffchange-inline">both victims consumed large amounts </del>of <del class="diffchange diffchange-inline">alcohol preceding their deaths </del>(<del class="diffchange diffchange-inline">blood alcohol concentrations (BAC</del>) <del class="diffchange diffchange-inline">were 2</del>.<del class="diffchange diffchange-inline">11 and 2.49 g</del>/<del class="diffchange diffchange-inline">L</del>, <del class="diffchange diffchange-inline">respectively</del>). <del class="diffchange diffchange-inline">Forensic autopsy </del>of <del class="diffchange diffchange-inline">both victims was performed four days after </del>the <del class="diffchange diffchange-inline">time </del>of <del class="diffchange diffchange-inline">death following </del>the <del class="diffchange diffchange-inline">Recommendation No.R </del>(<del class="diffchange diffchange-inline">99</del>)<del class="diffchange diffchange-inline">3 </del>of the <del class="diffchange diffchange-inline">Council </del>of <del class="diffchange diffchange-inline">Europe on medico</del>-<del class="diffchange diffchange-inline">legal autopsies</del>. <del class="diffchange diffchange-inline">Elegans demonstrated </del>the <del class="diffchange diffchange-inline">ability to form all </del>of the <del class="diffchange diffchange-inline">in-vivo </del>metabolites <del class="diffchange diffchange-inline">and has </del>the <del class="diffchange diffchange-inline">potential </del>to <del class="diffchange diffchange-inline">be used as a complementary model to predict </del>and <del class="diffchange diffchange-inline">characterize human metabolites, as well as identifying possible drug toxicities for emerging SCBs</del>. <del class="diffchange diffchange-inline">Thus, identification of the relevant urinary markers was based primarily upon the prevalence of the </del>in-vivo metabolites <del class="diffchange diffchange-inline">instead </del>of the <del class="diffchange diffchange-inline">metabolites ranking that was based upon % peak area abundance ratio. Moreover</del>, <del class="diffchange diffchange-inline">genetic makeup</del>, <del class="diffchange diffchange-inline">physiological conditions (age</del>, <del class="diffchange diffchange-inline">gender Read A great deal more </del>and <del class="diffchange diffchange-inline">ethnicity)</del>, <del class="diffchange diffchange-inline">environmental influences (diet) and pathological factors (liver diseases, diabetes</del>, and <del class="diffchange diffchange-inline">obesity) would </del>further <del class="diffchange diffchange-inline">complicate the </del>metabolism of <del class="diffchange diffchange-inline">drugs. It should be noted that % peak area abundance ratios do not necessarily reflect absolute concentrations due to differences </del>in <del class="diffchange diffchange-inline">ionization capacity </del>and <del class="diffchange diffchange-inline">matrix effects bias </del>for <del class="diffchange diffchange-inline">each metabolite.&lt;br&gt;Victim B also brought &quot;something resembling </del>a <del class="diffchange diffchange-inline">drug&quot; </del>(<del class="diffchange diffchange-inline">unrecognizable by Witness A</del>) <del class="diffchange diffchange-inline">from his cousin (Witness B) in </del>a <del class="diffchange diffchange-inline">cigarette box </del>and <del class="diffchange diffchange-inline">mixed this substance with </del>their <del class="diffchange diffchange-inline">tobacco</del>. The <del class="diffchange diffchange-inline">half</del>-<del class="diffchange diffchange-inline">maximal effective concentration (EC50) </del>of 4F-MDMB-BINACA <del class="diffchange diffchange-inline">is 5</del>.<del class="diffchange diffchange-inline">69 nM (</del>2.<del class="diffchange diffchange-inline">76–11</del>.<del class="diffchange diffchange-inline">0 nM) on CB1</del>, <del class="diffchange diffchange-inline">and </del>0.<del class="diffchange diffchange-inline">69 nM (0</del>.<del class="diffchange diffchange-inline">30–1</del>.<del class="diffchange diffchange-inline">56 nM) on CB2</del>, in <del class="diffchange diffchange-inline">vitro half-life (t1</del>/<del class="diffchange diffchange-inline">2) is 10</del>.<del class="diffchange diffchange-inline">27 min . It is usually available as </del>a <del class="diffchange diffchange-inline">powder</del>, <del class="diffchange diffchange-inline">liquid (vapor fluid)</del>, <del class="diffchange diffchange-inline">or herbal plant mixtur</del></div></td><td class='diff-marker'>+</td><td style="color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins class="diffchange diffchange-inline">To evaluate whether </ins>the <ins class="diffchange diffchange-inline">changes of coordinative functions by CNS damages were due to test substances</ins>, <ins class="diffchange diffchange-inline">rota-rod test was </ins>performed <ins class="diffchange diffchange-inline">using Rota-rod apparatus (Daejong, Seoul, Korea). The </ins>test <ins class="diffchange diffchange-inline">apparatus </ins>for <ins class="diffchange diffchange-inline">the locomotor activity </ins>test <ins class="diffchange diffchange-inline">was designed to measure </ins>locomotor activity <ins class="diffchange diffchange-inline">automatically using UV system (AM 1051, Benwick Electronics</ins>, <ins class="diffchange diffchange-inline">Benwick</ins>, <ins class="diffchange diffchange-inline">UK) when experimental animals moved in the chamber</ins>. In <ins class="diffchange diffchange-inline">both tests</ins>, <ins class="diffchange diffchange-inline">a group </ins>of <ins class="diffchange diffchange-inline">mice were treated with negative control (vehicle, 1 mg/kg, i.p</ins>.<ins class="diffchange diffchange-inline">)</ins>, <ins class="diffchange diffchange-inline">positive control </ins>(<ins class="diffchange diffchange-inline">methamphetamine, 1 mg/kg, i.p.</ins>)<ins class="diffchange diffchange-inline">, or one </ins>of <ins class="diffchange diffchange-inline">the three doses </ins>of <ins class="diffchange diffchange-inline">test substances </ins>(0.1, 1, 5 mg/kg<ins class="diffchange diffchange-inline">, i</ins>.<ins class="diffchange diffchange-inline">p</ins>.<ins class="diffchange diffchange-inline">) once every other day </ins>for <ins class="diffchange diffchange-inline">10 day</ins>&lt;br&gt;&lt;br&gt;<ins class="diffchange diffchange-inline">Synthetic cannabinoids </ins>have <ins class="diffchange diffchange-inline">consistently </ins>been <ins class="diffchange diffchange-inline">shown to </ins>produce <ins class="diffchange diffchange-inline">discriminative stimulus </ins>effects <ins class="diffchange diffchange-inline">similar to those of Δ9</ins>-<ins class="diffchange diffchange-inline">THC </ins>(<ins class="diffchange diffchange-inline">Bannister and Connor</ins>, <ins class="diffchange diffchange-inline">2018</ins>), and <ins class="diffchange diffchange-inline">MDMB-FUBINACA fully substituted for Δ9</ins>-<ins class="diffchange diffchange-inline">THC </ins>(<ins class="diffchange diffchange-inline">Gamage </ins>et al., 2018<ins class="diffchange diffchange-inline">&lt;br&gt;&lt;br&gt;&lt;br&gt;Buy Jwh-210 at USA K2 INCENSE STORE and enjoy premium quality, flexible quantities, and fast, secure shipping</ins>. <ins class="diffchange diffchange-inline">Fast shipping and pure product-highly recommended </ins>for <ins class="diffchange diffchange-inline">anyone needing quality incense ingredients</ins>.<ins class="diffchange diffchange-inline">&quot; 🌟🌟🌟🌟🌟 You can buy jwh</ins>-<ins class="diffchange diffchange-inline">210 online in quantities </ins>of <ins class="diffchange diffchange-inline">JWH</ins>-<ins class="diffchange diffchange-inline">210 powder 10g, 30g, 50g, 100g, 150g</ins>, and <ins class="diffchange diffchange-inline">200g at USA K2 INCENSE STORE </ins>for <ins class="diffchange diffchange-inline">premium quality and discreet shipping</ins>. <ins class="diffchange diffchange-inline">In some areas</ins>, <ins class="diffchange diffchange-inline">it is classified </ins>as a <ins class="diffchange diffchange-inline">controlled substance</ins>, <ins class="diffchange diffchange-inline">while </ins>in <ins class="diffchange diffchange-inline">others, it may be legal </ins>for <ins class="diffchange diffchange-inline">research or incense use. The legal status of jwh</ins>-<ins class="diffchange diffchange-inline">210 varies by country </ins>and <ins class="diffchange diffchange-inline">region</ins>.&lt;br&gt; <ins class="diffchange diffchange-inline">Key Features and Specifications to Evaluate </ins>&lt;br&gt;<ins class="diffchange diffchange-inline">In case of cannabis or Δ9-tetrahydrocannabinol, there are many JWH-210 powder previous studies regarding with their dependence potential and neurotoxicity (Cororan, et al., 1974; Harris, et al.</ins>, <ins class="diffchange diffchange-inline">1974; Leite </ins>and <ins class="diffchange diffchange-inline">Culini, 1974; Hutcheson, et al., 1998)</ins>. <ins class="diffchange diffchange-inline">After administering test substances once every other day for 10 days, brain samples </ins>of mice were <ins class="diffchange diffchange-inline">collected</ins>, <ins class="diffchange diffchange-inline">especially at nucleus accumbens </ins>and <ins class="diffchange diffchange-inline">hippocampus regions. Drug </ins>was <ins class="diffchange diffchange-inline">administered 5 times every other day, </ins>and <ins class="diffchange diffchange-inline">the first trial was performed </ins>2 h <ins class="diffchange diffchange-inline">after </ins>the <ins class="diffchange diffchange-inline">last administration</ins>.&lt;br&gt; <ins class="diffchange diffchange-inline">How to Choose Powder JWH-210 </ins>&lt;br&gt;<ins class="diffchange diffchange-inline">This dual-use nature underscores the importance </ins>of <ins class="diffchange diffchange-inline">responsible sourcing </ins>and <ins class="diffchange diffchange-inline">strict adherence to legal frameworks</ins>. <ins class="diffchange diffchange-inline">Forensic labs</ins>, <ins class="diffchange diffchange-inline">public health researchers</ins>, and <ins class="diffchange diffchange-inline">customs officials use authentic samples like JWH-210 to distinguish between legal and illegal compounds in seized materials. For those seeking </ins>a <ins class="diffchange diffchange-inline">dependable </ins>compound <ins class="diffchange diffchange-inline">for analytical purposes</ins>, <ins class="diffchange diffchange-inline">JWH</ins>-<ins class="diffchange diffchange-inline">210 Chemical Powder provides a trusted and effective solution. With its carefully controlled production process</ins>, <ins class="diffchange diffchange-inline">stable composition</ins>, <ins class="diffchange diffchange-inline">and secure packaging</ins>, <ins class="diffchange diffchange-inline">it remains a valuable resource for laboratory-based researc&lt;br&gt;&lt;br&gt; In histopathological analysis</ins>, <ins class="diffchange diffchange-inline">neural cells </ins>of the <ins class="diffchange diffchange-inline">animals treated with </ins>the <ins class="diffchange diffchange-inline">high dose </ins>(<ins class="diffchange diffchange-inline">5 mg/kg) of JWH</ins>-<ins class="diffchange diffchange-inline">081 or JWH</ins>-<ins class="diffchange diffchange-inline">210 showed distorted nuclei and nucleus membranes in the core shell of nucleus accumbens</ins>, <ins class="diffchange diffchange-inline">suggesting neurotoxicit&lt;br&gt;&lt;br&gt; The findings produce an apparent paradox</ins>, <ins class="diffchange diffchange-inline">since CPP and self</ins>-<ins class="diffchange diffchange-inline">administration predict with high reliability the likelihood that a compound will be abused by humans</ins>, and <ins class="diffchange diffchange-inline">cannabinoids are well</ins>-<ins class="diffchange diffchange-inline">known to </ins>produce <ins class="diffchange diffchange-inline">active </ins>drug-<ins class="diffchange diffchange-inline">seeking </ins>in <ins class="diffchange diffchange-inline">human</ins>&lt;br&gt;&lt;br&gt;&lt;br&gt;<ins class="diffchange diffchange-inline">When clinical presentation and/or initial DOA testing results are inconclusive, additional testing with </ins>LC<ins class="diffchange diffchange-inline">-</ins>QTOF-MS <ins class="diffchange diffchange-inline">can be valuable </ins>and <ins class="diffchange diffchange-inline">is recommended. SCRAs </ins>and <ins class="diffchange diffchange-inline">other NPS may not be detected by point-</ins>of<ins class="diffchange diffchange-inline">-care DOA tests</ins>. <ins class="diffchange diffchange-inline">In this case, the point-of</ins>-<ins class="diffchange diffchange-inline">care DOA urine screening was not able to detect the synthetic cannabinoid ADB</ins>-<ins class="diffchange diffchange-inline">BUTINAC&lt;br&gt;&lt;br&gt;&lt;br&gt;Effects </ins>of <ins class="diffchange diffchange-inline">individual doses were compared </ins>to the <ins class="diffchange diffchange-inline">vehicle control value using a priori contrasts. Response-rate data were analyzed by </ins>one<ins class="diffchange diffchange-inline">-way repeated-measure analysis </ins>of <ins class="diffchange diffchange-inline">variance. Percent drug</ins>-<ins class="diffchange diffchange-inline">appropriate responding was shown only if at [https:/</ins>/<ins class="diffchange diffchange-inline">cannabinoidsrc4f-adb</ins>.<ins class="diffchange diffchange-inline">com/ JWH</ins>-<ins class="diffchange diffchange-inline">210 powder] least three rats completed the first fixed ratio</ins>, <ins class="diffchange diffchange-inline">whereas all rats are shown </ins>for the <ins class="diffchange diffchange-inline">response rate dat</ins>&lt;br&gt;&lt;br&gt;&lt;br&gt;<ins class="diffchange diffchange-inline">Product ions detected at m/z 302, 217, and 145 (B2) confirmed </ins>that <ins class="diffchange diffchange-inline">tert-leucine and indazole moieties remained unchanged, leading to the structure elucidation of a hydroxy-functional group at the 4-position </ins>of <ins class="diffchange diffchange-inline">the butyl side chain by oxidative defluorination. The product ion m/z 336 </ins>(<ins class="diffchange diffchange-inline">loss of methyl ester moiety</ins>) <ins class="diffchange diffchange-inline">further confirmed the presence of dihydroxylated metabolites</ins>. <ins class="diffchange diffchange-inline">The precursor ion, m</ins>/<ins class="diffchange diffchange-inline">z 364 (B14</ins>, <ins class="diffchange diffchange-inline">B5/B6</ins>) <ins class="diffchange diffchange-inline">had a loss of 2 Da from m/z 366 indicated further dehydrogenation of the ester hydrolysis plus monohydroxylated metabolites</ins>. <ins class="diffchange diffchange-inline">The presence </ins>of the <ins class="diffchange diffchange-inline">product ion m/z 320, likely formed from a loss </ins>of <ins class="diffchange diffchange-inline">carbon dioxide, indicated monohydroxylation at </ins>the <ins class="diffchange diffchange-inline">tert-leucine in B8 (m/z 219), butyl side chain in B9 (m/z 145) and indazole moiety in B13 </ins>(<ins class="diffchange diffchange-inline">m/z 161</ins>)<ins class="diffchange diffchange-inline">. The precursor ion, m/z 350 showed a loss </ins>of <ins class="diffchange diffchange-inline">14 Da explaining </ins>the <ins class="diffchange diffchange-inline">hydrolysis </ins>of <ins class="diffchange diffchange-inline">methyl ester from 4F-MDMB</ins>-<ins class="diffchange diffchange-inline">BINACA.&lt;br&gt; Fig. 2</ins>. <ins class="diffchange diffchange-inline">&lt;br&gt;The precursor ion m/z 396 (B10, B12/B15) was 32 Da higher than the parent drug, 4F-MDMB-BINACA, suggesting </ins>the <ins class="diffchange diffchange-inline">addition </ins>of <ins class="diffchange diffchange-inline">two hydroxy groups. All </ins>the <ins class="diffchange diffchange-inline">below explanations for transformations into </ins>metabolites <ins class="diffchange diffchange-inline">are based on </ins>the <ins class="diffchange diffchange-inline">data shown in Fig. Metabolites were identified according </ins>to <ins class="diffchange diffchange-inline">their precursor ions, product ions, </ins>and <ins class="diffchange diffchange-inline">fragmentation patterns (Fig. 1)</ins>. <ins class="diffchange diffchange-inline">Traditional </ins>in-vivo <ins class="diffchange diffchange-inline">metabolism studies to generate human </ins>metabolites of <ins class="diffchange diffchange-inline">drugs relied heavily on </ins>the <ins class="diffchange diffchange-inline">use of whole animal model systems</ins>, <ins class="diffchange diffchange-inline">which are expensive</ins>, <ins class="diffchange diffchange-inline">limited by drug administration amount</ins>, <ins class="diffchange diffchange-inline">influenced by species variation </ins>and <ins class="diffchange diffchange-inline">faced by many ethical issues. Eight in-vivo metabolites tentatively identified were mainly products of ester hydrolysis with or without additional dehydrogenation</ins>, <ins class="diffchange diffchange-inline">N-dealkylation</ins>, <ins class="diffchange diffchange-inline">monohydroxylation </ins>and <ins class="diffchange diffchange-inline">oxidative defluorination with </ins>further <ins class="diffchange diffchange-inline">oxidation to butanoic acid.&lt;br&gt; Fig. 1. &lt;br&gt;Monitoring </ins>metabolism of <ins class="diffchange diffchange-inline">synthetic cannabinoid 4F-MDMB-BINACA via high-resolution mass spectrometry assessed </ins>in <ins class="diffchange diffchange-inline">cultured hepatoma cell line, fungus, JWH-210 powder liver microsomes </ins>and <ins class="diffchange diffchange-inline">confirmed using urine samples The threshold </ins>for <ins class="diffchange diffchange-inline">fatal overdose of combined use of SCRAs and ethanol can be estimated as </ins>a <ins class="diffchange diffchange-inline">little ng/mL </ins>(<ins class="diffchange diffchange-inline">0.37–4.1 ng/mL according to the reported cases</ins>) <ins class="diffchange diffchange-inline">of SCRA and 1.5–2.5 g/L of ethanol. The reported cases and reviews of the scientific literature suggest </ins>a <ins class="diffchange diffchange-inline">possible synergistic effect between SCRAs </ins>and <ins class="diffchange diffchange-inline">ethanol, because their combined use clearly increases </ins>their <ins class="diffchange diffchange-inline">toxicity</ins>. The <ins class="diffchange diffchange-inline">victim died due to severe necrotizing pancreatitis and acute kidney injury evolving into multi</ins>-<ins class="diffchange diffchange-inline">organ failure 11 days after hospital admission . Studies have found no unequivocal synergistic effect between THC and ethanol at low or moderate ethanol doses [29, 30], but no data on high doses of ethanol are available. Given that THC and ethanol act on the same receptors, data on their simultaneous use may yield important insights in this regard.&lt;br&gt; Fungus C. elegans &lt;br&gt;Concentrations </ins>of 4F-MDMB-BINACA <ins class="diffchange diffchange-inline">in the postmortem blood samples were 2</ins>.<ins class="diffchange diffchange-inline">50 and </ins>2.<ins class="diffchange diffchange-inline">34 ng/mL, which are in line with published data</ins>. <ins class="diffchange diffchange-inline">Although the lethal dose of 4F-MDMB-BINACA is unknown</ins>, <ins class="diffchange diffchange-inline">its concentration in postmortem blood samples was found to range between </ins>0.<ins class="diffchange diffchange-inline">10 and 2</ins>.<ins class="diffchange diffchange-inline">90 ng/mL </ins>. <ins class="diffchange diffchange-inline">In SCRA-related cases in which the deceased suffered from heart disease</ins>, <ins class="diffchange diffchange-inline">the SCRA concentration </ins>in <ins class="diffchange diffchange-inline">the postmortem blood was less than 1 ng</ins>/<ins class="diffchange diffchange-inline">mL </ins>. <ins class="diffchange diffchange-inline">Concentrations of SCRAs in postmortem cases cover </ins>a <ins class="diffchange diffchange-inline">wide range ; however</ins>, <ins class="diffchange diffchange-inline">some reports of survival have also been published—even at relatively high blood SCRA concentrations [19</ins>, <ins class="diffchange diffchange-inline">20</ins></div></td></tr> <!-- diff cache key stadtwiki:diff::1.12:old-28412:rev-28425 --> </table>

AlizaMoberg10